Isolation and characterisation of antibacterial agents produced by soil bacterium V3. by Khumalo, Lindiwe Lucia.
Isolation and Characterisation of antibacterial agents 
produced by soil bacterium V3 
Submitted in fulfilment of the requirements 
for the degree of 
MASTER OF SCIENCE (Chemistry) 
By 
Lindiwe Lucia Khumalo 
August 2006 
School of Chemistry and Chemical Technology 
University of KwaZulu-Natal 
Pietermaritzburg 
DECLARATION 
I hereby certify that this research is a result of my own investigation which has not 
already been accepted in substance for any degree and is not being submitted in canditure 
for any other degree. 
I hereby certify that this statement is correct 
Signed 
Lindiwe Lucia Khumalo 
Signed $£9.?^. 
Dr A. M. Soares 
Supervisor 
School of Chemistry and Chemical Technology 







CHAPTER 1 1 
NATURAL PRODUCTS AND DRUG DISCOVERY 1 
1. Introduction 1 
1.1 Definition 1 
1.2 Classifications 2 
1.2.2.1 Antifungal 16 
1.2.2.2 Antivirals 19 
CHAPTER 2 22 
2. ANTIBIOTICS (ANTIBACTERIALS) 22 
2.1. Antibiotics Discovery 22 
2.1.1 Definition 22 
2.2 Classification of Antibiotics 23 
CHAPTER 3 59 
3. RESULTS AND DISCUSSION 59 
3.1 INTRODUCTION 59 
3.2 BACTERIAL GROWTH PRODUCTION CURVE 62 
3.3 ISOLATION OF THE BACTERIOSTATIC AGENT 66 
3.3.1 Extraction and chromatography 68 
3.3.1.3 Chromatotron separation 69 
3.3.2 Bioassay Monitoring 69 
3.3.3 Structural elucidation of active compound by Nuclear Magnetic 
Resonance Spectroscopy (NMR) 72 
3.3.3.1 'H NMR Spectrum 72 
3.3.3.2 l3C NMR Spectrum 73 
3.3.3.3 'H-HCOSY 74 
3.3.3.4 JH-l3CHMQCandHSQC 75 
3.3.3.5 Infra Red Spectroscopy (IR) 78 
3.3.3.6 Mass Spectrometry 80 
3.3.3.7 X-ray studies of anthranilic acid. 82 
3.3.4 ACID-BASE EXTRACTION 85 
3.3.5 ELECTROPHORESIS 88 
3.3.6 ISOLATION OF ANTHRANILIC ACID BY PRECIPITATION 92 
3.4 FATE OF ANTHRANILIC ACID 93 
3.4.1 Anthranilic acid as a precursor 93 
3.4.2 Anthranilic acid as a metabolic degradation product 101 
3.4.3 Anthranilic acid as a secondary metabolite 102 
3.5 CONCLUSION 
103 
4. EXPERIMENTAL 105 
4.1 Materials and Methods 105 




I would like to thank God Almighty for the strength to overcome all the difficult times 
that I have been through. 
I would also like to thank my supervisor Dr. A. M. Soares for the support, advices and 
encouragement throughout this project. 
My sincere gratitude goes to Dr. M.R Low for the parenthood figure he showed in all the 
difficult times I had. Thanks also to all my lecturers at Chemistry department for building 
me up to this level. A special word of thanks is extended to Professor Fanie van Heerden 
for all the help she has provided as well as contributing to my success. 
I would also like to thank Professor O. Q Munro for solving the crystal structure and 
helping with the crystallographic data. I am grateful to Dr. Mervin Beukes at Genetics 
department for the assistance with the electrophoresis, and would also like to thank 
Tommy van der Merwe at University of Witwatersrand for the help with the mass 
spectroscopy results. Thanks to the National Research Foundation (NRF) for financial 
support. 
I also grateful acknowledge all the Warren "warriors" including all the postgraduate 
students, Prof Drewes and technical staff members Raj Somaru and Faizel Shaik for 
being there for me and providing help in all the times. Thanks to everyone at Chemistry 
department for making this department a place to be. I am also indebted to Craig 
Grimmer for all the assistance that he has provided as well as proofreading my work. For 
the microbiological part of work, I would like to thank all the technical staff at 
Microbiology department and Vincent Okudoh for proving the soil bacterium. 
1 
Finally I would like to thank my family for the love and support that they have shown all 
the way through. Thanks to my friends for making research enjoyable and for their 































doublet of doublets 
doublet of doublet of doublet 
distortionless enhancement by polarisation transfer 
FK 506-binding protein 
gas chromatography 
gas chromatography-mass spectroscopy 
hertz 
heteronuclear multiple quantum correlation 






mammalian target of rapamycin 
natural products 
para 
parts per million 
singlet 
species 




Actinomycetes are bacteria belonging to the order of Actinomyceteles and are 
characterised by the formation of branching filaments giving them a fungal appearance. 
These bacteria are widespread in nature and can be separated into two subgroups: the 
oxidative forms mostly in soil habitants, and fermentative forms, living in natural cavities 
of man and animals. 
The aim of this project was to isolate and characterise the antibacterial agents produced 
by a soil bacterium (V3). This bacterium was isolated from the KwaZulu-Natal midlands 
soil by Vincent Okudoh. Although not fully characterised, V3 bacterium belongs to the 
oxidative subgroup of Actinomycetes. The bacterium V3 was inoculated into the nutrient 
broth, and this broth was shaken for 48 hours in a 30°C water bath. The growth 
production curve was performed so as to determine at what stage was the antibacterial 
agent produced using this inoculated broth. After determining the stage at which the 
antibacterial agent was produced, the seed broth was prepared for two days and was used 
as the starting material for the fermentation of broth for 14 days. Different extraction 
methods including normal solvent/ solvent extraction, basic, acidic and neutral extraction 
methods were done to get a faster and easier method for extracting the antibacterial 
compound. Moreover, it was also important for the method to improve the yield as well 
as lessening the steps involved in the isolation of antibacterial agent. 
After doing these extraction procedures, it was found that the isolated compound was 
neither a base nor an acid, as it was not able to extract it by basic and acidic methods. It 
was then assumed that this antibacterial agent behaves like an amino acid. The isoelectric 
focusing was performed to get the pH at which the antibacterial compound precipitated 
out of solution. The precipitate was filtered and dried in an oven overnight, and its gas 
chromatography was recorded. Different instrumental techniques including NMR, IR and 
GC-MS were carried out to determine the structure of the antibacterial agent. The isolated 
antibacterial agent was found to be anthranilic acid, and the structure was confirmed by 
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x-ray crystallography. Gas chromatography was used to compare the isolated 
antibacterial compound with commercial anthranilic acid and it was found that the two 
compounds have the same retention time. 
Further studies were done to determine if the isolated antibacterial compound was the 
final product or the intermediate to the formation of the final product that actually inhibits 
the growth of microorganisms. Different screening tests were carried out to check if the 
isolated antibacterial agent was able to inhibit the growth of certain microorganisms 
including Serratia marsescens, Pseudomonas fluoscens, Staphylococcus aureus, 
Escherichia coli, Streptococcus faecalis and Candida utilis. It was found that anthranilic 
acid was able to inhibit the growth of all these microorganisms but was most active 
against Serratia marsescens and Pseudomonas fluoscens. 
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Chapter 1 
Natural Products and Drug Discovery 
1. Introduction 
"Natural products" originate from a wide variety of living organisms and serve different 
purposes. In addition to those that have essential roles in human life, such as vitamins and 
nutrients, some are noxious and act as defense mechanisms against predators, while others 
paralyse prey. Yet others may have no obvious purpose but are metabolic end products that 
may possess properties from useful to harmful. (For example genistein, widely distributed in 
plants, which in animals can disrupt endocrine function). 
Throughout the ages, humans have depended on nature for their survival, and as a result 
natural products traditionally have played an important role in drug discovery and were the 
basis of most early medicines.1 In this discussion, natural products will be defined and then 
classified according to chemical classes that are commercially available. They will also be 
classified according to their medicinal use; finally, with particular attention to antibiotics. 
1.1 Definition 
According to Strohl, natural products are secondary metabolites produced by organisms in 
response to external stimuli such as nutritional changes, infection and competition. Examples 
of widely used natural products include lovastatin (anticholesterol agent) (1), cyclosporin A 
(2), and tacrolimus FK506 (immunosuppressive agents) (3), paclitaxel (4) which was formerly 
known as taxol and is an important anticancer drug, and doxorubicin (5), trade name valstar, 
that is widely used in oncology as an antitumor agent.1 These natural products are shown in 
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Figure 1: Examples of natural products. 
1.2 Classifications 
1.2.1 Industrial-Production-Based Classification System 
In the pharmaceutical industry drugs that have natural product origin can be divided into three 
different groups: the unmodified natural products, semisynthetic and natural products-derived 
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synthetic compounds. If a natural product is produced synthetically for medicinal use, it is still 
defined as a natural product. Natural products-derived compounds are synthetically derived 
from a natural product template. In the pharmaceutical industry medicinal agents are subjected 
to some rigorous standards of efficacy, safety and purity as approved by regulatory agencies 
such as Food Drug Authority (FDA) in America and Medicines Control Council (MCC) in 
South Africa. 
1.2.1.1 Unmodified Natural Products (NP) 
The chemical structures of natural products can be diverse and complex. Nature provided the 
earliest medicinal agents both as complex mixtures from botanical, marine and microbial 
preparations and as single drug substances long before synthetic organic chemistry developed 
to the stage where it could be an important route to new drugs. Natural products continue to be 
important today as a source of new drugs. 
Natural products are compounds isolated directly from natural sources and these are not 
modified after isolation but they are used as they are obtained from natural sources. Examples 
include galantamine (6) that can be purchased commercially as Reminyl, an important drug in 
treating Alzheimer's disease, as well as mycophenolic acid (7), known as myfortic with 
immunosuppressive activity, the structures of which are shown in Figure 2. The opium 
alkaloids are important analgesic drugs, and continue to be manufactured by processing opium 
exudates and extract. The immunomodulatory cyclosporins originally isolated from the soil 
fungus Trichoderma polysporum, and tacrolimus (FK-506) (3) (Figure 1), a secondary 
metabolite isolated from Streptomyces tsukabaensis, are used to suppress immunological 
rejection of transplanted organs.3 These unmodified natural products represent a major 
breakthrough for organ transplantation. 
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Figure 2: Examples of unmodified natural products used in the pharmaceutical industry. 
Natural products have provided the most important successes in the chemotherapy of cancer. 
Most of the major anticancer drugs are unmodified natural products obtained from plants or 
microorganisms and include such important drugs as bleomycin, doxorubicin, daunorubicin, 
vincristine, vinblastine, mitomycin, streptozocin and paclitaxel (Taxol™). Vincristine and 
vinblastine are complex dimeric indole-indolines obtained from the rose periwinkle 
{Catharanthus rosea), and are among the most important therapies for the treatment of 
childhood leukaemia, Hodgkin's disease and metastatic testicular tumours. These unmodified 
natural products continue to be produced today by mass cultivation and processing of the plant 
material. 
More recently, a complex diterpene, isolated from the bark of the pacific yew tree and named 
taxol, has been reported to possess significant cytotoxicity to cancer cells.4 Although it took 
some fifteen years for the potential of paclitaxel (Figure 1) to be realised, it is now recognized 
as a breakthrough in the treatment of ovarian and breast cancers and is one of the most 
exciting new drugs in recent history. Currently, both a semisynthetic derivative with improved 
water solubility, docetaxel (Taxotere®), and paclitaxel (Taxol®) are approved and used 
clinically. 
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1.2.1.2 Synthetic Natural Products 
Substances produced by chemical synthesis from basic chemical building blocks are utilized 
for a variety of purposes and have proliferated over the last half century as synthetic 
methodology and production technology have developed to highly sophisticated levels. 
Modern drug research is now predominantly based on substances produced by chemical 
synthesis, which involve the use of computer-aided drug design, combinatorial libraries and 
structural optimisation of lead compounds of both natural and synthetic origin to maximize the 
benefit-risk ratio. 
However, the discovery of bioactive natural products, which serve as leads for new drugs, 
remains an important drug discovery strategy. In the following discussion, two case studies 
will be conferred, the first one includes the cholesterol lowering agents and the second one 
involves the antimalarial quinolone drugs. The clinically useful cholesterol-lowering agents 
known as the "statins" are derived from natural products isolated from a fungus. These drugs 
inhibit 3-hydroxy-3-methyl glutaryl coenzyme, a reductase (HMG-CoA reductase), and an 
enzyme critical in the biosynthesis of cholesterol. The first such agent, compactin, was 
initially reported as an antifungal agent.5 However, once its mechanism of action was 
determined, a search for other naturally occurring HMG-CoA reductase inhibitors led to the 
discovery of lovastatin (1), a metabolite of the fungus Aspergillus terreus that was first 
introduced to the market in 1989. 
Many analogs, both semisynthetic and totally synthetic were later prepared, and from these, 
several have become important drugs, including simuvastatin (8) (launched 1991), pravastatin 
(9) (1991) and atorvastatin (10) (1997) (Figure 3). The latter, a chiral, totally synthetic 
compound, has become the drug of choice in the therapeutic category based on its superior 
ability to reduce cholesterol at low doses. The development of the statins is a very good 
example of natural product-based discovery of an important new drug class followed by 
optimisation of properties yielding improved drugs. It illustrates the interconnection between a 
natural product and its semisynthetic and total synthetic analogs and the determining role of 
molecular structure, whether constructed by nature or humans with respect to drug properties. 
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1 Lovastatin: R = H R'= CH3 
8 Simvastatin: R = CH3 R' = CH3 





Figure 3: Structures of synthetic and semisynthetic statin drugs. 
With the quinolones the main focus will be on the important antimalarial drugs primaquine, 
chloroquine and mefloquine, which were all patterned after the alkaloid quinone, the active 
constituent of the fever tree Cinchona succiruba. When the natural source of quinoline 
derivatives based on quinine was threatened during the second world war, massive programs 
to synthesize a multitude of quinoline derivatives based on the quinine prototype ensued, and 
the aminoquinolines cited above were among some of the successful drugs to emerge from this 
extensive effort. The effort to design better antimalarial agents led also to the discovery of 
other important anti-infectives, including a class of synthetic antibacterials that is among the 
most prescribed in clinical use today, the floroquinolones. Therefore, the quinolone anti-
infective agents are purely of synthetic origin and are not modelled after any known natural 
antibiotic. 
The first antimicrobial quinolone was discovered about fifty years ago as an impurity in the 
chemical manufacture of chloroquine. It demonstrated a small extent activity towards Gram-
negative bacteria, not enough to pursue as a therapeutic agent. However, following on this 
lead, research subsequently resulted in the production of nalidixic acid (11), which was used 
mainly for urinary tract infections. The sales of these agents were not impressive but this 
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picture changed with the discovery of norfloxacin (12) and shortly thereafter, ciprofloxacin, 
ofloxacin and levoflaxin. In fact, ciprofloxacin and levoflaxin are among the top hundred most 
frequently prescribed drugs worldwide. Pharmaceutical companies are making huge profits 
from the manufacture of these compounds. 
As a result, nalidixic acid (11) was first commercialised and thus is known as the first-
generation quinolone. Nalidixic acid was found to be bactericidal in action, and had the 
advantage of being easily synthesized, and was a convenient orally-active drug. Though 
nalidixic acid is considered as a good drug, there were limitations to its use, for example, it 
was found that it had poor pharmacokinetic properties as well as the problem of resistance. 
The search for other quinolones continued until the first second-generation quinolone 
norfloxacin (12) was discovered. 
Researchers are constantly searching for more accessible and shorter syntheses. Norfloxacin 
(12) was the breakthrough molecule as its potency and spectrum of activity approximated 
those of the fermentation-derived antibiotics. Although quinolone antibiotics are of synthetic 










Figure 4: Structures of quinolone antibiotics. 
The discovery of new quinolone antibiotics is an on-going process and has led to the recent 
development of the third-generation quinolones. Other fluoroquinolones belong to the group 
of third-generation quinolones. They are the group of synthetic antimicrobial agents that show 
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excellent potencies and a broad spectrum of activity against different Gram positive as well as 
Gram-negative bacteria. These are widely used in the treatment of infectious diseases. The 
antibacterial activity of fluoroquinolones depends on the bicyclic heteroaromatic 
pharmacophore as well as the nature of the peripheral substituents and their spatial 
relationship. 
All fluoroquinolones interfere with DNA transcription, replication and repair and thus leading 
to bacterial cell death. The mode of action of quinolones is similar to that of aminoglycoside 
antibiotics in that the bacterial killing is concentration dependent rather than dosage-interval 
dependent and fluoroquinolones possess post antibiotic action lasting for 1-2 hours.6 
As mentioned earlier, quinolones have a synthetic origin, and there are many synthetic 
methods reported in the literature, for example the Gould-Jacobs reaction, Grohe-Heitzer 
Q 
reaction and the Chu-Mischer synthesis. The Gould-Jacobs reaction involves reaction 
between a substituted aniline and a substituted ethylenemalonate at high temperatures as 
shown in Scheme 1. The first step is the addition-elimination step; followed by cycloacylation. 
This is then followed by alkylation step, which is an SN2 mechanism step since the alkyl 







Scheme 1: Basic Gould-Jacobs reaction. 
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The second basic method is the Grohe-Heitzer reaction shown in Scheme 2. Initially, it 
involves the acylation of the aromatic ring so that the substituents are present in the acid as the 
starting material as well as the final product. The first step involves the conversion of a 
benzoic acid derivative into a benzoylacetate ester. This is followed by the condensation of 
methylene function with an ortho ester under dehydrating conditions. The enol ether formed is 
subjected to an addition-elimination reaction with a primary amine, and the resulting product 
cyclizes by an addition-elimination reaction. 
COCI 
MgCH(C02Et)2 
+ ^ XJ±. 
H+ 
C 0 2 E t RNH 
CI ^ N H R 
,COCH2C02Et 
C02Et 
CI ^ O E t 
Scheme 2: Basic Grohe-Heitzer reaction. 
The most effective and shortest method of synthesizing quinolones is by the Chu-Mischer 
synthesis (Scheme 3). This method involves the use of a chiral a-amino alcohol and the 







NH2 cycloaracylation C02Et 
Scheme 3: Chu-Mischer synthesis. 
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1.2.1.3 Semisynthetic Natural Products (Semisynthetic NP) 
Semisynthetic natural products have been modified by genetic engineering or chemical 
synthesis in order to improve their properties. Examples include the numerous antibiotic 
semisynthetic penicillins, cephalosporin drugs and vitamin derivatives that have improved 
stability. 
The semisynthetic natural products that will be discussed include erythromycin (13) (Figure 
5), an important antibacterial agent commercialized as Ketek®. The second semisynthetic 
natural product is sirolimus (also known as rapamycin, (17)), an immunosuppressant agent 
whose trade name is Certican (Figure 6) and finally the third examples of semisynthetic 





13 Erythromycin: R = H 





Figure 5: Structures of erythromycin and its structural analogues9'10 
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Erythromycin (13) and its second-generation derivatives clarithromycin (14), roxithromycin 
(15) and azithromycin (16) (Figure 5) are the most widely used macrolide antibiotics. 
Erythromycin derivatives have gained interest for their potential use in the treatment of 
gastrointestinal disorders and inflammatory diseases and also as precursors for the synthesis of 
ketolides used in the treatment of emerging drug-resistant bacterial strains. Clarithromycin has 
been synthesized by methylation of the C6-OH group of erythromycin, whereas roxithromycin 
has been produced by the insertion of an etheroxime chain at the C9 position. It has been 
assumed that the higher inhibitory activity of clarithromycin (14), roxithromycin (15) against 
Gram-negative bacteria, compared with that of erythromycin, is because of their enhanced 
ability to penetrate the cell envelope of Gram-negative cells. Azithromycin (16) is also derived 
from erythromycin (13). However, it differs chemically from erythromycin in that a methyl-
substituted nitrogen atom is incorporated into the lactone ring. This change has resulted in an 
improved acid stability and is two to eight times more active against H. influenza.6 
Structural modifications have also been made to sirolimus (17) which is also known as 
rapamycin, an important immunosuppresant and an anticancer therapeutic agent. It has been 
used widely due to its binding ability to two different proteins, FKBP and mTOR. After 
structural modification of rapamycin (17) to Fl-rapamycin (18), the binding affinity increased 
200-fold/ 
17 Rapamycin R = H 
18 F1 -Rapamycin R = •f/W 
c °2 F y^° 
OH 
Figure 6: Structures of rapamycin alongside its structural analogue. 12-14 
11 
The incidence of malaria has dramatically increased worldwide, because malarial parasites 
have developed resistance to the commonly-used drugs. This has motivated the discovery of a 
sesquiterpene endoperoxide, isolated from a Chinese medicinal herb.3 Following the discovery 
of artemisinin, different derivatives have been synthesized. The semisynthetic analogues 
shown in Figure 7 are preferred to the original drug itself because they have higher efficacy. 
This high activity against resistant Plasmodium falciparum strain is due to their unusual 
structures. Researchers have agreed that the presence of the endoperoxide group in artemisinin 
compounds is responsible for its high activity, though the real mechanism of antimalarial 
activity for these compounds is still not known. 
Deoxyartemisinin Carboxypropyldeoxyartemisinin 
Figure 7: Structures of artemisinin and its structural analogues. 
Cheng and co-workers" reported that the poor solubility of artemisinin restricts its 
employment. As a result, structural modification especially at carbon 12 in artemisinin (19), 
lead to improved solubility. A series of ether and ester derivatives have been semisynthesized. 
12 
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However, Chang-Hun and co-workers determined that the deoxyartemisinin (21) and 
carboxypropyldeoxyartemisinin (22) are more effective against the malarial parasite and this is 
due to their lipophilicity. Due to this lipophilicity, they also target specific proteins in cancer 
cells. 
It has been reported that the highly reactive endoperoxide in artemisinin is changed to free 
radicals by the iron in the free heme molecules concentrated in the food vacuoles of malarial 
parasites and the resulting free radicals lead to cellular destruction. 
1.2.1.4: Natural Product-Derived Drugs 
However useful they may be, natural products may have several drawbacks. For instance, they 
may have an impractically short half-life, cause allergic side effects and may be unstable. All 
these limitations could potentially be overcome either by molecular modifications during the 
biosynthesis of these drugs, by a chemical synthetic process, or by employing an enzymatic 
process. 
Sheehan and co-workers in 1953 accomplished the total synthesis of penicillins and some 
other approaches have also been successful. 4 These syntheses are of limited practical value, 
because of the presence of the lactam ring, which is complex to synthesise, nevertheless, they 
allow modification of the ring system. On the other hand, the discovery of the parent amine 
6-aminopenicillanic acid (6-APA) in fermentation products constituted a major breakthrough 
in penicillin synthesis. It is formed by acylases that cleave off the side chain of the penicillins, 
a process that can also be obtained by the selective chemical cleavage of the amide, leaving 
the lactam intact. After this, 6-APA can be easily acylated by any carboxylic acid and this has 
yielded thousands of natural product-derived penicillins with improved stability and activity. 
Table 1 shows some of these antibiotics that are available commercially. Methicillin (24), 
phenethicilin (26) and oxacillin (27) are lactamase resistant whereas others such as ampicillin 
(28) are not only orally active but have a broad spectrum of activity. Carbenicillin (25) is 
particularly active against some microbes such as Pseudomonas and Proteus that are not 
affected by penicillin. 
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Table 1: Some commercially available natural product-derived penicillins 
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Elsamicin A Trichostatin A 
Figure 8: Examples of natural product-derived compounds. 
Other examples of natural product-derived compounds (Figure 8) include elsamicin A (29), 
commercially known as elsamitrucin, and trichostatin A (30) known commercially as 
suberoylanilide hydroxamic acid. Elsamicin A (29) is an antitumor antibiotic with a 
fascinating chemical structure and is a good candidate for pharmaceutical development. The 
amino substituted glycosyl group of elsamicin A takes part in DNA binding and hence 
antitumor activity. It inhibits RNA synthesis and causes single-strand scission of DNA via the 
formation of free radicals. Elsamicin A is also regarded as the most potent inhibitor of 
topoisomerase II reported so far, whereas trichostatin A is an antifungal antibiotic produced by 
Streptomyces platensis. 
1.2.2 Biological Activity Based Classification 
Natural products can also be classified according to their biological activity. In the following 
section, antifungals, antivirals, and finally, antibiotics (antibacterials) will be discussed. 
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1.2.2.1 Antifungal 
The incidence of severe, invasive and opportunistic fungal infections in immunocompromised 
patients is increasing at an alarming rate. The most common fungal pathogens are Candida 
and Aspergillus sp. 
Antifungal drugs for serious infections are either fungistatic (fluconazole, traconazole, that is, 
azoles) and vulnerable to resistance or fungicidal (amphotericin B - polyene macrolide) but 
toxic to the host. A newer option, the enchinocandins are fungicidal and less toxic to the host 
by virtue of their novel mode of action. Targets for action of antifungal agents are given in 
Table 2. Cell-wall acting agents are a new class of antifungals with a novel mode of action 
and are inherently selective and fungicidal in nature. Three classes of such compounds, target 
respectively, P-1,3 glucan synthase (echinocandins - a derivative of pneumocandin B0), 
chitin synthase (nikkomycins) and mannoproteins (pradimicins and benanomicins), were 
explored for clinical development. 
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Most of the antifungal drugs that are used to date are natural products, but there are also semi-
synthetically derived antifungal agents. The natural occurring antifungal agents are the 
polyenes and griseofulvin, and the semisynthetic ones include the echinocandins. The 
polyenes are naturally occurring polyketides isolated from various Streptomyces species and 
have broad antifungal activity. The mechanism of action of polyenes involve complexation 
with ergosterol and thus destabilization of the fungal cell membrane and this results in fungal 
death. The structures of two polyenes are shown in Figure 9, partricin A (31) and 
amphotericin B (32). Amphoteric B is commonly used to treat fungal infections, but has 
serious side effects, which can be reduced by liposomal preparations. 
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Figure 9: Examples of naturally occurring polyenes. 
The echinocandins are a group of naturally occurring lipopeptides produced by various fungal 
species and display antifungal activity by inhibition of 1,3-P-D-glucan synthesis in the fungal 
cell wall.15"16 Examples of echinocandins are: anidulafungin (33) and aminocandin (structure 
not available), which are semisynthetic derivatives of echinocandin B (34) and 
deoxymulundocandin (35), respectively. 
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Deoxymulundocandin 
Figure 10: Examples of echinochandins. 
1.2.2.2 Antivirals 
Viral diseases such as human immunodeficiency virus (HIV), influenza, and yellow fever are 
known to cause a great health risk in humans, thus a need for the discovery of antiviral drugs 
has grown considerably. 
19 
Viruses are difficult to target, mainly because they use the metabolic enzymes of their host. 
One of the most important medical tools for dealing with them is vaccination, that is, using the 
immune system of the host. However, not all viral infections can be cured in this manner. 
Some antiviral drugs have been developed to act on the host-cell recognition and insertion 
phases of viral attack, which involve protein-protein and protein-carbohydrates interactions. 
Most of today's successful antiviral agents target nucleic acid metabolism. Most nucleic acid 
synthesis inhibiting drugs are nucleoside analogues with an altered sugar base or both as 
shown in Figure 11. Acyclovir (Zivirax) (36) is the best example of a DNA polymerase 
inhibitor. When it gets incorporated into DNA, it acts as a chain terminator. Azidothymidine 
(AZT®, Retrovir®, Zidivudine®) (38) is also a chain terminator used against human 
immunodeficiency virus (HIV). 
Natural Template Synthetic Analogue 
HN 






Figure 11: Examples of Nucleotides used in Natural Products Templates. 
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Different compounds have been isolated, and synthetic work has been done so as to get drugs 
that will treat viral diseases, especially HIV. Examples of these compounds shown in Figure 
12 include the PA- 457 (39), a semi-synthetic derivative of the plant triterpenoid betulinic acid 
(40). Betulinic acid (40) was found to be a weak inhibitor of HIV replication.' Furthermore, 
calanolide A, which was isolated in a small quantity from the plant source Calophyllum 
lanigerum, was found to have activity against HIV and also against Mycobacterium 
tuberculosis, thus patients suffering from tuberculosis as well as HIV can be treated with 
calanolide A (41). 
C02H 
41 Calanolide A 
Figure 12; Structures of some antiviral drugs 
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Chapter 2 
2. Antibiotics (antibacterials) 
2.1. Antibiotics Discovery 
The study of antibiotics started in 1929 when Alexander Fleming discovered penicillin from 
•J 
the fungus Penicillium notatum, followed by its use as a therapeutic agent around 1940. The 
discovery of penicillin led to the exploration of nature as a source of biological active agents. 
As a result, microorganisms were then considered as an important source of structurally 
different bioactive metabolites and have provided a convenient way for obtaining 
pharmaceutically useful compounds. Before the introduction of antibiotics in the 1940s and 
1950s, patients infected with bacteria in the blood stream had no chance of survival; as a result 
antibiotics were hailed as miracle drugs because they rapidly cured infections that would 
otherwise have proven fatal.3 
2.1.1 Definition 
Antibiotics (antibacterials) were traditionally defined as chemical compounds produced by 
microorganisms of which a small amount has the ability to kill or inhibit the growth of other 
microorganisms. Recently, antibiotics have been defined as substances synthesised from 
certain bacteria, fungi and other organisms, that can destroy or inhibit the growth of other 
microorganisms. 
Hammond et al. defined antibiotics as substances produced by microorganisms antagonistic 
to the growth or life of others at high dilution (but excluding organic acids, peroxides and 
alcohols produced by many microorganisms). According to Hutter et alls antibiotics are the 
products of secondary metabolism with an incidental action in minimal concentration on 
growth processes. There are five major lines of attack by which the antibiotic can attack the 
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cell, namely, by inhibiting the cell wall synthesis, inhibiting cell membrane synthesis or 
permeability, inhibiting nucleic acid replication, inhibiting protein synthesis and interfering 
with cell metabolism. The need to continue discovering new antibiotics is crucial as microbes 
mutate very fast and soon become resistant. Natural products have played a crucial role in the 
development of antibacterial agents. These include the pMactams (which were introduced in 
1941), aminoglycosides (1944), cephalosporins (1945), chloramphenicol (1949), tetracyclines 
(1950), macrolides (1952), lincosamides (1952), streptogramins (1952), glycopeptides (1956), 
rifamycins (1957) and lipopeptides (2003). ' There are a few antibacterials which are 
synthetically derived, these include sulfonamide (1935), nitroimidazole (1959), quinolone 
(1962), trimethoprim (1968) and oxazolidinone (2000). Microorganisms have been an 
important source in discovery of the above-mentioned antibacterial agents. This project has 
focused on novel antibacterials from soil microorganisms. 
2.2 Classification of Antibiotics 
There are four classifications of systems of antibiotics: 
• The classification according to the modes of action of compounds, that is, whether they 
are cell-wall or cell-membrane inhibitors. 
• They may also be classified based on the antibiotic producing organism, for example, 
production of penicillin or cephalosporin by the molds Penicillium notatum and 
Cephalosporium, respectively. 
• Another classification is based on the chemical structure as well as biosynthetic 
pathway by which antibiotics are formed. 
• Lastly, Kahne and co-workers have classified antibiotics into two ways depending on 
the manner in which they target pathogens. The first way is by the nature of the targets in 
susceptible bacteria, for example blocking of bacterial cell wall biosynthesis, or protein 
synthesis. The second way is whether the antibiotic is derived from a natural product 
(synthetic antibacterial drug). 
In our work, however, the classification according to the mode of action as well as 
classification according to the chemical structure will be followed. 
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Most antibacterial agents act by inhibiting the synthesis of RNA, DNA or peptidoglycan. The 
peptidoglycan is a mesh-like carbohydrate polymer that provides mechanical support 
necessary to prevent the cells from lysing when the osmotic pressure fluctuates. The 
antibiotics that inhibit the peptidoglycan are derived from natural products. These antibiotics 
are divided into three classes (Figure 13) depending on their mechanism of action. The first 
class includes the P-lactams, carbapenems, and cephalosporins. These antibiotics inhibit the 
enzyme's active sites that catalyze transpeptidation and thereby preventing glycan cross-
linking, for example oxacillin (42). The second class includes moenomycin (44), an important 
additive to commercially available animal feed; it inhibits the glycan polymerization by 
binding to the bacterial transglycosylases. The third class includes the ramoplanin, members of 
lantibiotic family of antibiotics and glycopeptides, for example, vancomycin (43) that binds to 





Figure 13: Examples of three classes of antibiotics inhibiting peptidoglycan. 
2.2.1 p- Lactam antibiotics 
p-Lactam antibiotics are a group of antibiotics having a common characteristic lactam ring. 
There are a number of antibiotics belonging to this group, including penicillin (sulfur-
containing penams), cephalosporin (sulfur-containing cephems), natural and synthetic 
monocyclic p-lactams, which include carbapenems, oxapenams, carbacephems, and 












Figure 14; Examples of (3-lactam antibiotics. 15 
p-Lactam antibiotics are one of the three largest groups of antibiotics that play an important 
role in the preservation of human health. The other two groups are the macrolides and the 
fluoroquinolones, which will be dealt with elsewhere. P-Lactam antibiotics and their 
derivatives act by inhibiting the bacterial cell wall by binding to the penicillin binding protein 
which is a protein responsible for the cross linking step in cell wall biosynthesis. Bronson23 
and co-workers reported that the carbapenems are divided into two major categories; these are 
novel parenteral carbapenems and novel orally-active pro-drugs of carbapenems. The 
parenteral carbapenems play an important role in improving the pharmacokinetic properties 
relative to imipenem and meropenem, whereas the orally-active pro-drugs are useful at 
targeting broader clinical usage since such agents would be used in settings outside the 
hospital.9 
P-Lactam antibiotics inhibit the bacterial cell wall and cause the lyses of the cell, and thus 
result in cell death. The bacterial cell wall has peptidoglycan that is also known as the murein 
sacculus. The normal biosynthesis of the bacterial cell wall is shown in Scheme 4. The 
binding of the P-lactam antibiotic leads to the weakening of the cell, and thus death of the 
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bacterium. Scheme 5 shows binding of the cephalosporin antibiotic and thus changing 
normal structure of the cell. 
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Scheme 5: Incorporation of cephalosporin onto the bacterial cell. 
The discovery of penicillin from a mould contaminant led to the discovery of other (3-lactam 
antibiotics produced by soil organisms, especially the soil bacteria, as shown in Figure 15. 
Hedge and co-workers24 reported a secondary metabolite SCH 42282 (49), with antifungal 
activity that was isolated from the fermentation broth of a soil Actinomycete identified as a 
Microtetraspora spp. The search for antimicrobial agents from soil of different places 
continued and led to the discovery of a new macrocyclic lactam antibiotic, BE-14106 (50) 
isolated from a soil sample collected in Shiroyama-cho, Mie Prefecture, Japan25 This antibiotic 
(50) was found to be produced by Streptomyces spheroids and has been shown to have both 
cytotoxic activity against the murine leukaemia cell line and antimicrobial activity.10 
Moreover, this antibiotic was found to be a 19-membered macrocyclic lactam. It has been 
noted that different lactam antibiotics have been isolated from different soil environments, as a 
,26 
result Igarashi and co-workers reported a novel 19-membered macrolactam antibiotic, 
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cremimycin (51), the antibiotic having been isolated from Streptomyces species, which belong 
to the members of Actinomycete. Cremimycin was found to have broad antimicrobial activity 
against Gram-positive bacteria. Another known antibiotic in this group is a macrocyclic 
lactam, possessing a P -phenylalanine substituent, which was isolated from cultured broth of an 
Actinomycete strain, and was found to be an antiprotozoal. Biosynthetically, it originates from 
malonate, methylmalonate and phenylalanine via the polyketide pathway. 
Figure 15: Examples of /3-lactam antibiotics isolated from soil bacteria. 
2.2.2 Glycopeptide and Lipoglycopeptide Antibiotics 
The two most important glycopeptide antibiotics used clinically, vancomycin (43) and 
teicoplanin (52) are shown in Figure 16. These antibiotics are important in the treatment of 
bacterial infections that are resistant to other antibiotics like the P-lactam antibiotics. 
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Figure 16: Examples of glycopeptide antibiotics. 
28 Gao reported that vancomycin was isolated from a soil sample collected by the Eli Lilly 
Company in the mid-1950's. This antibiotic was first used in 1959 and is produced by 
Streptomyces orientalis. Due to the complexity of the structure, structural elucidation of 
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vancomycin was not easy to achieve. Structural elucidation started back in 1965 and was 
completed in 1996 when Sheldrick achieved elucidation of the complete structure.10 
In this discussion we will summarise what is known about the structure and the function of the 
glycopeptide antibiotics, and consider how natural and semisynthetic lipoglycopeptides are 
developed into new therapeutic agents. Both vancomycin (43) and teicoplanin (52) are similar 
as they contain a heptapeptide chain, the amino acid sequence of which is not necessarily the 
same. However, vancomycin (43) is a glycopeptide that has an acylated glycosyl peptide, 
whereas teicoplanin (52) does not only have a glycosyl group but also a lipid chain. 
2.2.2.1 Mode of Action of Vancomycin and Teicoplanin 
•y i 
Kahne and co-workers reported that the mechanism of action of glycopeptide antibiotics, 
especially vancomycin, involves binding to the peptidoglycan precursors, specifically to the 
D-Ala-D-Ala terminus. The binding was shown to occur through a set of backbone contacts 
between the D-Ala-D-Ala dipeptide and the amides that line a cleft formed by the cross-linked 
heptapeptide of the glycopeptide. Through binding to the D-Ala-D-Ala, the bound 
glycopeptide acts as an impediment that prevents lipid II and the nascent glycan chain from 
being processed further. This leads to the inhibition of the transglycosylation and 
transpeptidation steps of the peptidoglycan synthesis that ends up weakening the 
peptidoglycan layers leaving the cell susceptible to lyses because of the changes in osmotic 
pressure of the cell. The mechanism of action of vancomycin is illustrated in Figure 17. 
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Figure 17: Binding of vancomycin with N-acyl-D-Ala-D-Ala termini, five hydrogen bonds 
between the underside of the glycopeptide and the acyl-D,D- dipeptide. ' 
Williams and co-workers found that the lipidated glycopeptides are attached to the bacterial 
cell membrane, whereas nonlipidated glycopeptides are distributed more broadly in the 
peptidoglycan layers.3 ' ' Due to the lipophilic nature of teicoplanin it has been rationalised 
that it inserts itself into the membrane, where peptidoglycan precursors terminating in D-Ala-
D-Ala are located. This results in the location of these binding partners in close proximity, 
which leads to the intramolecular interaction between the two, which is more favoured than 
the intermolecular interaction. Therefore, Williams and co-workers deduced that it is the 
restriction of motion of intermediates and the intramolecular bond formation that allow 
teicoplanin (52) to overcome the vancomycin resistance. 
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2.2.2.2 Biosynthetic Strategies 
The total synthesis of the vancomycin (43) and teicoplanin (52) family has been accomplished 
with the intervention of new chemistry. However, the complexity of the structures of these 
natural products makes fermentation a more cost-effective and viable route to the bulk 
product. It has been reported in the literature that the synthesis of most glycopeptide 
antibiotics, for example vancomycin (43) is tiresome, due to low yields obtained and the 
cumbersome number of steps involved. ' ' These include the assembly of the amino acid 
components of glycopeptide antibiotics into the heptapeptide backbone by a mechanism 
known as the multienzyme thiotemplate mechanism. This mechanism involves recognition 
and activation of each amino acid by a suitable enzyme module; this is then followed by the 
covalent linking of the enzyme complex to the amino acid through a thioester-pantetheine 
cofactor unit. A peptide bond is then formed between the two enzyme-bound units. Successive 
epimerization and further coupling completes the synthesis. 
Structural analogues of these compounds have been achieved by semisynthetic methods. A 
variety of methods have been employed so as to synthesise these compounds and these include 
the construction of amino acid building blocks, formation of a linear heptapeptide, oxidative 
coupling processes, glycosidations and reductive alkylation of the amino group of the 
vancosamine sugar in vancomycin (43) to yield oritavancin (53). Furthermore, feeding 
i ~y 
experiments in vancomycin-producing bacteria with [1,2- d ] acetate showed that the m-
dihydroxyphenylglycine (AA-7) of vancomycin is formed through the polyketide pathway of 
four units of acetate. It should be noted that all glycopeptide antibiotics isolated to date are 
mainly produced by Actinomycetalis. Few of these glycopeptides are from the Streptomyces 
and the majority are from the Actinomycetes that was originally classified as Nocardia. 
Most bacteria have strategies for self-protection and immunity from the action of chemical 
weapons, which are antibiotics, thus leading to resistance problems. This also happened to 
glycopeptide antibiotics, as a result some chemical modifications had to be made to 
vancomycin to give oritavancin (53), which was more effective than vancomycin. Due to the 
complex structure of vancomycin, synthetic routes were not used and chemical method was 
preferred to give (53). This method involves a single step reductive alkylation of the amino 
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group of the vancosamine sugar in vancomycin to give oritavancin (53) as shown in 
Scheme 6. Malabarba and co-workers reported three strategies for chemical modification 
of glycopeptide antibiotics to overcome problems of resistance; these include modifications in 
the structure of the binding site, synthesis of covalently linked dimmers, as well as the 
alterations of the disaccharide moiety of vancomycin.15 
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of Amino Group 
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Oritavancin 
Scheme 6: Reductive alkylation of the amino group of vancosamine sugar in 
vancomycin to form oritavancin. 
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2.2.3 Peptide Antibiotics 
The search for new antibiotics is a continuous process, because of resistance problems. Zhang 
and co-workers37 reported a new cyclic peptide antibiotic zelkovamycin (54) (Figure 18), 
which was isolated from the fermentation broth of Streptomyces sp. K96-0670. It has been 
found that zelkovamycin has antibacterial activity against a number of organisms, including 





Figure 18: Structure of zelkovamycin. 
Different natural products researchers have discovered different antibiotics from different 
environments, this includes Schimana and co-workers who discovered three lipopeptide 
antibiotics from the mycelium extracts of Streptomyces sp.38 These lipopeptide antibiotics 
were found to be colourless arylomycin All (55), arylomycin AIII (56), and a yellow 
arylomycin AIV (57), (Figure 19). These arylomycins have antibacterial activity against 
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Figure 19: Examples of arylomycins. 
Kimura and co-workers reported the three liposidomycins, which were produced by 
Streptomyces sp. SN-1061M. These liposidomycins were found to be important in inhibiting 
the peptidoglycan synthesis and thus are cell wall inhibitors. These liposidomycins A (II) to 
(IV) 58-60 are shown in Figure 20. 
H02C 58 R ' - c 1 3 H 2 3 ^ ^ 
C 1 3 H 2 3 
HO 
R" = S04H Liposidomycin A-(II) 
59 R'= Y ^ Y ' ^ l f R" = OH Liposidomycin A-(III) 
O CH3 O 
60 R'= cwH23ViS«!^y R" = OH Liposidomycin A-(1V) 
Figure 20: Examples of liposidomycins 
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2.2.4 Aminoglycoside Antibiotics 
Magnet et al defined aminoglycosides as hydrophilic molecules consisting of a characteristic 
central aminocyclitol linked to one or more amino sugars by pseudoglycosidic bond(s). 
According to Vladimir, the name aminoglycoside refers to the group of antibiotics 
containing aminosaccharides joined by a glycosidic bond. Aminoglycosides are the most 
important group of carbohydrate antibiotics used clinically. The first antibiotic isolated in this 
group was streptomycin (61) which was discovered by Waksman et al. in 1943,1'42 and was 
found to be useful in the treatment of tuberculosis. There are other different types of 
aminoglycoside antibiotics that were discovered after streptomycin (61), these include 
kanamycin (62), amikacin (63), gentamicin B (64), tobramycin (65), netilmicin (66).17 
Streptomycin, which was the first antituberculosis agent to be discovered,16 differs from the 
other aminoglycoside antibiotics in that it has the streptidine ring as the central aminocyclitol, 
whereas other aminoglycosides have 2-deoxystreptamine as the central aminocyclitol to which 
glycosidic bonds attach different amino sugars instead of the streptidine ring as shown in 
Figure 21. 
All aminoglycosides are bacteriostatic, and their bacterial killing activity is concentration 
dependent, that is, the higher their concentration is, the greater the rate at which they kill 
bacteria. ' Furthermore, aminoglycosides are polycations and their polarity is in part 
responsible for the pharmacokinetic properties shared by all members of the group. They all 
target the small ribosomal subunit by inhibiting the translation process. 
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Figure 21: Examples of aminoglycoside antibiotics. 
2.2.5 Tetracyclines 
Tetracycline antibiotics (Figure 22) are all yellow amphoteric substances forming salts with 
acids or bases or complexes with such metals as aluminium, magnesium, calcium or iron.45 All 
tetracyclines are protein synthesis inhibitors. Tetracyclines have found widespread use since 
their discovery was first reported in 1948.46 There are six members of tetracycline antibiotics 
and all these are produced by actinomycetes. These include chlortetracycline (67) (1948), 
oxytetracycline (68) (1949), tetracycline (69) (1953), and declomycin (70) (1957) (Figure 22). 
All tetracycline antibiotics contain a hydronaphthacene skeleton as a characteristic structural 
unit.25'47 Tetracyclines are divided into natural and semi-synthetic tetracyclines. The natural 
tetracyclines include chlortetracycline (67), oxytetracycline (68), and declomycin (70), which 
are produced by Streptomyces. The semi-synthetic ones are methacycline (1965), doxycycline 
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(1967), minocycline (1972) and tigilcycline (1993). Tigilcycline is undergoing phase (III) 
clinical trials. 48 
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Figure 22: Examples of natural tetracycline antibiotics. 
2.2.6 Macrolides Antibiotics 
Macrolides antibiotics are a group of closely related compounds having a macrocyclic lactone 
i o 
ring (usually containing 14 or 16 atoms) to which deoxy sugars are attached as shown in 
Figure 23. Katz4 reported that the first person who originally proposed the definition of 
macrolides is R.B. Woodward, and he defined the term macrolide as an abbreviation of 
macrolactone glycoside antibiotics, which is a class of natural products composed of a 
macrocyclic lactone ring to which one or more deoxysugar residues are attached. Furthermore, 
Katz and co-workers reported that macrolides are secondary metabolites produced by the 
actinomycete family of bacteria. The three known secondary metabolites belonging to the 
macrolides group were reported by Bertram and co-workers, these include the erythromycin 
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(13), azithromycin (16) and clarithromycin (14). There are natural as well as semi-
synthetically produced macrolides. 
The first macrolide antibiotic discovered in 1950 was pikromycin (71).24 This was then 
followed by the discovery of erythromycin (13), by Mcquire and co-workers in 1952 from 
Streptomyces erythreus.12 The other two members of this group are semi-synthetic derivatives 
of erythromycin. The structures of these antibiotics are shown in Figure 23. Macrolide 
antibiotics were classified based on the chemical viewpoint by Katz and co-workers. These 
were divided into groups depending on the number of atoms in the macrocyclic ring,23 and 
there are 12, 14, 16 and even larger membered macrolide. These are further subdivided 
depending on the sugar substituent as well as the structure of the lactone ring. From the 
clinical point of view, macrolides are divided into the first, second and third generation 
depending on the year they were discovered. 
The first generation macrolides are natural products introduced in the 1950s, followed by the 
semi-synthetic second generation compounds in 1990 and the semi-synthetic third generation 
molecules in the early 2000s. The present work has concentrated mainly on the macrolides 
that have been isolated as natural products; some macrolides are the congeners of the parent 
compound. Congeners are intermediates of the final products found in the late pathway. All 
macrolides are protein synthesis inhibitors; they bind to ribosome and thus block protein 
synthesis. 
2.2.6.1 Fourteen-Membered Macrolides 
There are five compound families belonging to this group, these include the erythromycin A 
(13) and its derivatives pikromycin (71), megalocin A (72), oleandomycin (73), and 
lankamycin (74) (Figure 23). Each family of compounds has some congeners belonging to it. 
All 14-membered macrolides have desosamine at C-5, except lankamycin (74), which has the 
neutral sugar chalcose at position 5. Pikromycin (71) also differs from other 14-membered 
macrolides in that the oxygen present at C-3 is in the form of a ketone, thus is known as a 
ketolide. This ketolide has a higher bacterial potency than erythromycin A. 
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^ ô Y 
73 Oleandomycin O 
H O / 0 -
OMe 
OH 
74 Lankamycin O 
OAc 
Figure 23: Examples of 14-membered macrolide antibiotics. 
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2.2.6.2 Twelve-Membered Macrolides 
The two known macrolides that contain twelve-membered rings are methymycin (75) and 
neomethymycin (76). These two antibiotics both contain a hydroxyl group, but differ in the 
position of the hydroxyl group. Methymycin (75) has a hydroxyl on C-10 position whereas 
neomethymycin has a hydroxyl group on C-12 position (Figure 24). 
NMe„ NMe. 
75 Methymycin 76 Neomethymycin 
Figure 24: Examples of twelve-membered macrolides. 
2.2.6.3 Sixteen-Membered Macrolides 
There are four different groups belonging to the 16-membered macrolide antibiotics, which 
differ in the structure of the polyketide backbone that forms the macrolactone. These include 
the tylactone group, platenolide group, mycinamicin, and the chalcomycin-neutramycin 
groups. 
2.2.6.4 Important Uses of Macrolides 
Macrolides can be classified into the first, second and third generations depending on their 
clinical use. The first generation macrolides are those that are isolated as the fermentation 
products, for example fermented broth, and then used clinically for the treatment of diseases. 
An example of a first generation macrolide is erythromycin A (13). This antibiotic is very 
effective but has several disadvantages including a bitter taste and causing stomach cramps. 
As a result chemical modification was necessary to avoid the use of erythromycin. The 
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chemical modification of erythromycin is shown in Scheme 7. Other disadvantages of using 
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Scheme 7: Chemical modification of the first-generation macrolide to form the second 
generation macrolide. 
Resistance problems emerged after the development of the second-generation macrolides and 
as a result some further chemical modification was necessary to form the third generation 
macrolides. Scheme 8 shows the modification of clarithromycin (14) to form telithromycin 
(77), which is the third generation macrolide with better activity than clarithromycin (14). 
There are eight chemical steps involved in the conversion of clarithromycin (14) to 
telithromycin (77). The first step is an acid hydrolysis of clarithromycin to give the 3-
descladinosyl derivative that is then acetylated with acetic anhydride so as to protect the 2 -
hydroxyl. Oxidation of the 3-hydroxyl to a ketone is then followed by the introduction of the 
11,12-cyclic carbamate. Treatment of the product with methanol results in removal of 2-
acetate group and then the formation of telithromycin (77). 
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Scheme 8: Chemical modification of the second-generation macrolide to form the third-
generation macrolide. 
2.2.6.5 Genetic Engineering in the Production of Macrolides. 
Early experiments have proved that macrolides are produced from acetate, propionate, and 
butyrate as starter units. This involves bioconversion of the compounds with five to nine 
carbons in the chain into the aglycones of macrolides. The aglycones are complex polyketides 
that are grouped together by consecutive decarboxylative condensations of carboxyl thioesters 
including malonyl CoA, methylmalonyl CoA; this is done in the same manner as for fatty 
acid biosynthesis. Each step of the synthesis is programmed to determine the acyl unit 
incorporated into the growing chain, and the degree to which the resulting P-carbonyl 
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49 generated from the condensation is reduced. This process is achieved by the use of 
polyketide synthase that catalyzes all the steps involved in aglycone assembly. Different 
enzymes are used for different steps as they perform a variety of functions. 
Module 5 Module 6 
Narbonolide 
Narbomycin 
Scheme 9: Genetic engineering in production of macrolides, all modules include 
ketosynthase (KS), acyltransferase (AT), acyl carrier protein (ACP), ketoreductase (KR), 
dehydratase (DH), and thioesterase (TE). 
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2.2.6.6 Mode of action of macrolides 
All macrolides are protein synthesis inhibitors and as a result they inhibit translation 
processes. The mechanism of action of these protein synthesis inhibitors differs in each and 
every group. Some macrolides bind to the 50S component of bacterial ribosomes and make 
specific interactions with the 23S RNA. Some macrolides, like the 16-membered macrolides, 
block the peptide bond formation by binding to the A site and thus block the binding of 
aminocyl tRNA; these macrolides are peptidyltransferase blockers. The erythromycin and 
other 14-membered macrolides were found to have no effect on the peptidyltransferase 
activity. 
2.2.7 Streptogramin Antibiotics 
Streptogramin antibiotics are natural product antibiotics produced by different members of 
Streptopmyces. These antibiotics are divided into two types, type A and type B, which are 
produced by the same bacterial species in a ratio of 70:30. Type A streptogramins are cyclic 
polyunsaturated macrolactones consisting of polyketide structures that are cyclized through 
an internal ester bond between the carboxyl of the C-terminus amino acid and an internal 
hydroxyl group as shown in Figure 25. Examples of Group A streptogramins are 
pristinamycin HA (82), madulamycin II (83) and the semisynthetic derivative dalfopristin (85). 
The biosynthetic origins of the components of group A, streptogramin pristinamycin IIA (82) 
have been investigated through traditional precursor fermentation experiments and the results 














































Figure 25: Examples of type A streptogramin antibiotics. 
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Figure 26: Biosynthetic origins of various components of group A streptogramin antibiotics. 
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Type B streptogramin antibiotics are cyclic hepta- or hexadepsipeptides, for example, 
pristinamycin IA (86), virginiamycin S2 (87), vernamycin C (88), patrician A (89) and the 
semisynthetic quinupristin (90) are shown in Figure 27. 
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Figure 27: Structures of type B streptogramins. 
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Streptogramins are protein synthesis inhibitors. They bind to the P site of 50S ribosome and 
thus block protein synthesis step. These antibiotics share a common mechanism of action with 
the macrolides, linconsamides, and thiopeptides, but the streptogramins type A and B are 
different from these antibiotics in that both type A and type B components are separately 
bacteriostatic but synergistically they exhibit a bactericidal activity. 
2.2.8 Chloramphenicol 
Chloramphenicol (91), (Figure 28), was found to be the second interesting antibiotic produced 
by Streptomyces, and it was discovered after streptomycin. This antibiotic is important 
because it was found to be the first antibiotic to be a derivative of dichloroacetic acid and 
nitrobenzene. Furthermore, it is active against a wide range of organisms including bacteria 
and viruses. Moreover, chloramphenicol attracted attention of most natural product chemists, 
because like ascorbic acid among the vitamins, it was the first antibiotic to be obtained in 
quantity by a synthetic process and as a result all commercial supplies of chloramphenicol are 
synthetic. Chloramphenicol is a bacteriostatic, broad spectrum antibiotic which inhibits 
microbial protein synthesis. 
OH H CI 
0 2 N ^ ^ ^ HO 
91 Chloramphenicol 
Figure 28: Structure of chloramphenicol antibiotic. 
2.2.9 Lantibiotics 
Lantibiotics are peptide-derived antimicrobial agents made by ribosomes. The name 
lantibiotics was introduced in 1988 and it is an abbreviation of lanthionine-containing 
antibiotic peptides.51 All natural lantibiotics have meso-stereochemistry and there are three 
groups of antibiotics belonging to this family. Examples of lantibiotics are shown in Figure 29 
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These are the nisin (92) group, subtilin (93) group as well as the epidermin (94) groups 
respectively. Nisin lantibiotic is produced by Lactococcus lactis and is widely used as a food 
preservative. There are two members of this group, the nisin A and Z, which differ from each 
other by one amino acid, which is Histidine in nisin A and Aspartic acid in nisin Z. The 
subtilin lantibiotic is produced by Bacillus subtilis and is structurally related to nisin; nisin has 
two more amino acids than subtilin. The third group of lantibiotics is the epidermin group, 
which consists of 22 amino acids, and was isolated from the Streptococcus mutans. All 
members of the epidermin group have a characteristic Lan ring between positions 3 and 7. 
Structures of different lantibiotics are shown in Figure 29. It should be noted that about 40 
lantibiotics are known and these differ from each other not only in structure but in size and 
mode of action. Some lantibiotics are prepared by chemical synthesis and chemical 
modification using processes such as the Merrifield synthesis. Protein engineering is the most 
viable route for preparing lantibiotics since the Merrifield synthesis takes too long due to the 
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Figure 29; Examples of lantibiotics. 
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Figure 30: Examples of thiopeptide antibiotics. 
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Thiopeptides are naturally-occurring, sulfur-containing, highly modified, macrocyclic 
peptides.52 These antibiotics are grouped as thiazolyl peptides in the Berdy classification 
system where they are classified according to the chemical structure.53 They all have tri- or 
tetrasubstituted nitrogen heterocycles clustered in a central polyazole domain that is part of 
macrocyclic ring containing heterocyclic residues like thiazoles, oxazole indoles and 
dehydroamino acids. All thiopeptide antibiotics are secondary metabolites produced by 
Actinomycetes especially the Streptomyces, and are biological active compounds. They all 
share a common property, that is, they are growth inhibitors for Gram-positive bacteria and 
have no activity against Gram-negative bacteria. They are all protein synthesis inhibitors. 
2.2.11 Antifolates 
Antifolate agents are mostly used clinically as antibacterials, antimalarials and anticancer 
drugs. They are bacteriostatic in nature and thus inhibit bacterial growth but do not actively 
kill the bacteria. Antifolates interfere with the biosynthetic pathway of tetrahydrofolic acid by 
inhibiting dihydropteroate synthetase, which is an enzyme responsible for the biosynthesis of 
folic acid. They also mimic p-aminobenzoic acid (PABA), which is essential for the 
biosynthesis of bacterial cell membrane. These drugs bind in the enzyme active site instead of 
PABA and have similar electrostatic properties to PABA. Therefore they act as competitive 
inhibitor of dihydropteroate synthetase. The structures of both antifolate sulfanilamide drug 
and PABA are shown in Figure 31. 
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Figure 31: Structures of PABA (79) and its competitive inhibitor sulfanilamide (80). 
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The administration of sulfanilamide, which is one of the antifolate drugs, causes bacterial to 
stop growing and dividing. This allows the host time to recognize and overcome the infection. 
These drugs are not toxic to humans since humans do not have dihydropteroate synthetase and 
thus do not biosynthesise tetrahydrofolic acid but obtain it from the diet (green vegetables and 
liver). All living cells need the tetrahydrofolate cofactor for the synthesis of purines, some 
amino acids and especially thymidine for growth purposes.5 The mechanism of action of 

























Acts as a 1-carbon source 
in the biosynthesis of purines 
Scheme 10: Mechanism for biosynthesis of folic acid and the action of antifolate, 
sulfonamide and trimethoprim. ' 
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2.2.12 Aims of the study 
Throughout the ages, humans have relied on nature for their basic needs including the 
production of foodstuffs, shelter, clothing, means of transportation, fertilizers, flavors and 
fragrances, as well as medicines. 9 Plants have formed the basis of the highly developed 
traditional medicines that have been in existence for thousands of years. Plant survival 
depends on certain climatic conditions such as temperature and moisture. Due to their 
inconsistent growing patterns they cannot be relied upon for the production of medicines. 
Furthermore, their over-exploitation by illegal chopping has resulted in the reduction of plant 
growth. For the above reasons soil microorganisms have been chosen for this study since they 
can be grown anytime, anywhere, and in large quantities. Additionally, the time to reach 
maturity is greatly reduced. 
The unanticipated discovery of penicillin from the fungus Penicillium notation by Fleming in 
1929, and its broad therapeutic use in the 1940's introduced a new era in medicine that is the 
discovery of antibiotics from microorganisms. This discovery also resulted in the intensive 
investigation of nature as a source of bioactive agents. Microorganisms are a productive 
source of structurally diverse bioactive metabolites and have yielded some of the most 
important products of the pharmaceutical industry. These include the antibacterial agents such 
as penicillins, cephalosporins, aminoglycosides, tetracyclines, polyketides, cholesterol 
lowering agents, and immunosuppressive agents. Many of these useful drugs are produced by 
Actinomycete, which are isolated from soil. 
Actinomycete are the biggest producers of bacterial secondary metabolites. The objective of 
this study is to extract and characterize an antibacterial agent produced by soil bacteria 
obtained from KwaZulu-Natal midlands soil (Pietermaritzburg). The polyene antifungal 
antibiotic, natamycin (pimaricin) (99) shown in Figure 32 was produced by Streptomyces 
natalensis was isolated from soil near Pietermaritzburg, South Africa. This antibiotic is widely 
used as a food preservative to control the growth of yeasts and moulds on the surface of 




Figure 32: Structure of natamycin (pimaricin). 
This study has been done as part of the global search for new secondary metabolites with new 
antibacterial, antifungal, antitumour, as well as herbicidal or pesticidal properties. The primary 
metabolites involved in secondary metabolite biosynthesis will be identified and also try to 
obtain as much information about the regulation of their synthesis as possible as this is 
necessary to further increase the yield of secondary metabolite production. 
The first steps in secondary metabolite biosynthesis usually involve a series of very specific 
enzymatic steps to synthesize a common building block. This compound is then derivatised 
via non-specific enzymes such as dehydrogenases, transferases, oxidases or other activities, 
acting in various combinations or sequences, resulting in an enormous diversity of chemical 
compounds such as end products. The exchange of genes coding for these non-specific 
enzymes, via natural combination or recombinant DNA techniques, has indeed lead to the 
formation of new hybrid secondary metabolites (metabolic pathway engineering).58 
Mutagenesis and selection of strains overproducing secondary metabolites is necessary to 
overcome the initially low rate of metabolite synthesis. In the initial strain improvement 
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procedure, the flux of the specific secondary metabolite biosynthesis pathways themselves 
may be increased in the production strains. Later, the availability of precursors from primary 
metabolism will be of influence. At this stage one may expect that increasing the flow towards 
these building blocks will also increase the productivity of secondary metabolite formation. 
Incorporation of structural analogues of the building blocks as alternative starter units would 
be expected to produce structural analogues of the secondary metabolite. 
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Chapter 3 
3. Results and Discussion 
3.1 Introduction 
Although not fully characterised, bacterium V3 belongs to the oxidative subgroup of the 
Actinomycetes. These are bacteria belonging to the order Actinomycetales and are 
characterised by the formation of branching filaments giving them a fungal appearance59 as 
shown in Figure 33. Actinomycetes are widespread in nature and can be separated into two 
subgroups: the oxidative forms mostly in soil habitats, and the fermentative forms, living in 
natural cavities of man and animals. 
Figure 33: Branching filaments formed by V3. 
Actinomycetes are undoubtedly the largest producers of bacterial secondary metabolites as 
shown in Table 3. Secondary metabolites are, in contrast to primary metabolites, not essential 
59 
for growth and are synthesized from intermediates, or end-products of primary metabolism via 
unique biosynthetic pathways. These pathways may have originated from primary pathways 
within the same organism but gene transfer between different organisms is also an important 
factor in the evolution of secondary metabolism.60 
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The bacterium (V3) used in this work was isolated by Vincent Okudoh from soil in the 
KwaZulu-Natal midlands. This bacterium was then inoculated onto the nutrient broth as 
described in the experimental section. Extraction was done using petroleum ether-ethyl acetate 
(1:1). Chromatography was used to purify the compounds produced by the bacterium. 
3.2 Bacterial Growth Production Curve 
Bacteria as a group live and grow under a wide range of environmental conditions. Because 
these microorganisms exert most of their effects through growth, knowledge of the processes 
involved with microbial growth is essential to the understanding, study and control of 
fundamental microbial activities. Bacteria can be studied at all stages of growth 
microscopically, physically, and chemically. The information acquired through such studies 
can be used to correlate the chemicals formed during growth with the appearance of cellular 
structures. Secondary metabolites are biosynthesised under sub-optimal conditions near the 
end of the exponential growth phase or in the stationary phase. 
Schlegel61 defined growth as the irreversible increase in living substances, which is 
accompanied by an increase in the size of cells and their division. The term growth as applied 
to microorganisms usually refers to an increase in the number of microorganisms or mass 
beyond that present in the original inoculum. A single bacterial cell continually increases in 
size until it is about double its original dimensions. It then divides and gives rise to two cells 
approximately the size of the original parent cell. All structural parts of the cell double during 
this cell growth division cycle. 
• The time required for the formation of two new cells from one is called the generation 
time. During this time, the population of cells doubles. Thus, starting with one 
bacterium, the increase in population follows a progressive doubling. 
• Cell populations can reach levels into the billions, so logarithmic notation that 
incorporates exponents of 10 is used to handle large numbers. 
• Bacteria and other unicellular microorganisms exhibit characteristic growth cycles or 
patterns, which can be divided into the four distinct growth phases: lag phase; 
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exponential or logarithmic phase; stationary phase; and death phase. Their general 
characteristics are as follows: 
1. Lag phase: During this phase, cells in a new inoculum adjust to the medium. Increases 
occur in enzyme production and cell size. 
2. Exponential or logarithmic phase: During this phase, cells and cell mass double at a 
constant rate. Metabolic activities proceed at a constant rate. Environmental conditions, 
which include pH, temperature, medium properties, etc., influence this phase. Because the 
doubling of the population (generation time) occurs at regular time intervals, this phase 
also is referred to as one of balanced growth. 
3. Stationary phase: During this phase, toxic products accumulate and/or the availability of 
nutrients decreases and the number of viable cells reaches a plateau, resulting from some 
cells dying and others still growing and dividing. There is no net increase or decrease in 
cell number. 
4. Death phase: If toxic substances accumulate and/or cell starvation occurs, the cells of the 
population enter this phase. The rate of decline becomes exponential with time. 
The easiest way to monitor bacterial growth is by using the spectrophotometer. 
Spectrophotometers are instruments that electronically quantify the kinds and amount of light 
that are absorbed by molecules in solution. Spectrophotometric measurements such as those 
described in this exercise are based on the Beer-Bouger Law ' , which shows the relationship 
between a solutions concentration of suspended particles and its transmission of light. This 
relationship provides the basis for the quantitative determinations of the concentration of 
bacterial cells in a solution by measurement of the light transmitted by the solution.64'65 
Normal white light is a mixture of light waves of many different wavelengths (colours) 
between 380 and 750 nanometers (nm). The eye and brain perceive these waves of different 
wavelengths as different colours. The growth measurements require that the light entering a 
solution (incident light) is monochromatic (composed of a single wavelength). A 
spectrophotometer is equipped with a device to separate white light into its component 
wavelengths. Absorbance (A), also called optical density (OD), is directly proportional to 
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concentration (particles suspended) when a solution behaves according to the Beer-Lambert 
Law (a modification of the Beer-Bouger Law). Absorbance specifically is the logarithm to the 
base 10 of the reciprocal of the transmittance. In this exercise, absorbance values were used to 
measure turbidity of the bacterial growth media. On spectrophotometers, the absorbance scale 
normally is present along with the transmittance scale. The spectrophotometer measures the 
intensity of light (at various wavelengths) before and after the light has passed through a 
solution. If the solution contains particles such as bacteria that absorb light, the concentration 
of the bacteria can be determined spectrophotometrically by measuring the absorption of light. 
The procedure for spectrophotometric measurements is relatively simple to perform. In 
general, it involves placing a solution of a light-absorbing particle into a cuvette (a special, 
small test tube), selecting the appropriate wavelength, and inserting the cuvette in the light 
pathway of a spectrophotometer so that the light passes through the cuvette and the solution it 
contains. Any light transmitted through the cuvette is directed onto a photosensitive device, 
which converts the radiant energy into electrical energy. A meter in the spectrophotometer 
then measures the electrical current generated. The absorbance, or percent transmission, is 
determined by comparing the value produced by the particle-containing solution to that of a 
blank solution, which does not contain the light-absorbing material. Note that standard plate 
counts and spectrophotometric measurements should be simultaneously done to follow the 
bacterial growth cycle and to obtain data with which to plot the corresponding growth curve. 
The growth production curve was determined by taking aliquots from the growth media at 
regular intervals and measuring their absorbance at 550 nm. This is the maximum wavelength 
at which the bacterial growth medium absorbs light. The results are shown in Figure 34. 
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Figure 34: Growth curve of the bacterium (V3). 
The four stages of a bacterial growth curve, namely the lag phase, exponential phase, the 
stationary phase and the death phase, are all present. As a general rule, the secondary 
metabolites are formed only when the growth rate of an organism is curtailed. In this study 
the harvesting of the secondary metabolite was done on the eighth day (near the end of the 
exponential phase or in the stationary phase). 
As shown in chapter two, the formation of antibiotics is directed by organized sets of genes 
associated with special regulatory mechanisms that control both the timing and the level of 
gene expression.66 Their physiological role is not known. Speculations about their functions 
include a role in overflow metabolism to get rid of excessive amounts of intermediates of 
primary metabolism. High intracellular concentrations of these intermediates can be toxic to 
the cell. If export of unmodified metabolites is not possible, their conversion into less toxic, or 
more easily exported metabolites, may provide a way to prevent build up of toxic 
intermediates. Another role of secondary metabolites may be in defense mechanisms. 
Inhibiting other competing cells would leave more nutrients for the survival of the secondary 
metabolite-producing strain. Indeed many secondary metabolites show antibacterial or other 
inhibitory activities such as anti-tumor, antifungal, or may function as herbicides. Various 
groups of secondary metabolites can be distinguished depending on the primary intermediates 
from which they are derived. This division, however, is not absolute because more than one 
primary metabolite may be involved in the biosynthesis of a particular secondary metabolite. 
4 0 0 6 0 0 
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Secondary metabolism is an intracellular process; however, few products have been reported 
to accumulate within the cytoplasm. Therefore, after determining the growth production curve, 
the next task was to find out using a bioassay whether the bacteriostatic agent was kept 
intracellular or excreted and hence more abundant in the growth medium. The biomass was 
separated and the cells or intracellular materials were studied to determine bacteriostatic 
activity. It was found that only the broth showed bacteriostatic action against Pseudomonas 
fluoscens as shown in Figure 35. 
Figure 35: Results obtained when testing bacteriostatic activity of the broth contents using 
Pseudomonas fluoscens. 
After determining that the compound with antibacterial action was in the broth, its isolation 
was then carried out, following the procedure outlined in Figure 36. 
3.3 Isolation of the Bacteriostatic Agent 
The experiment was started by inoculating the nutrient broth with V3 bacterium isolated from 
the soil. The seed broth was prepared for two days, and this was used as the starting material 
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for the fermentation of broth for 14 days. Two solvent systems, which are petroleum ether and 
ethyl acetate, were used for extracting the antibacterial agent. The petroleum ether aided in 
removing fatty acids and the ethyl acetate was then used for extracting the remaining organic 
components, which yielded a yellow solid that inhibited the growth of two bacterial 
microorganisms, Serratia marscences and Pseudomonas fluoscens. The other test organisms 
included the Staphylococcus auereus, Escherichia coli and the fungus Candida utilis. The 
isolated antibacterial agent was able to inhibit the growth of these microorganisms but their 
inhibition zones were not as distinct as those for Serratia marscences and Pseudomonas 
fluoscens. Chromatographic techniques including the chromatroton were employed so as to 
purify the isolated antibacterial agent. The whole procedure for the isolation of an antibacterial 
agent is shown in Figure 36. 
Petroleum ether extract 
{No Biological activity} 
{No biological activity} Aqueous extract Organic extract 
{Biological activity} 
Figure 36: Diagram showing different steps involved in extraction of the antibacterial agent. 
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This procedure involves the separation of compounds with different polarities and since the 
desired compounds will be soluble in one or another solvent, this technique is meant to 'clear' 
the solution by removing contaminants. Petroleum ether was used to extract the fermentation 
broth; it contained no microbial growth inhibitory compounds giving the false impression that 
isolation of the antibacterial agent would be a simple procedure. Petroleum ether was used as a 
defatting solvent to remove unwanted waxes and oils from the broth, which would otherwise 
interfere with further analysis. This also makes further separation easier by removing a large 
portion of unwanted material. As shown in Figure 36, ethyl acetate was then used to extract 
the fermentation broth. It contained the bacteriostatic agent. In fact, after the extraction of the 
broth by ethyl acetate, no antimicrobial activity was detected in the remaining aqueous broth. 
Attention was focused on the ethyl acetate extract. 
3.3.1 Extraction and chromatography 
3.3.1.1 Column chromatography 
Column chromatography is the most commonly used preparative technique for the isolation of 
chemical compounds. Initially it was thought essential to develop a good eluting system in 
order to separate components, therefore, much effort was taken to develop a good eluting 
system with the ethyl acetate fraction. A combination of methanol: ethyl acetate (1:10) and 
petroleum ether: ethyl acetate (3:7) was initially chosen as the former separated the polar and 
the latter the non-polar components and both components are volatile and easily removed from 
fractions. 
3.3.1.2 Preparative Thin-Layer Chromatography (TLC) 
Preparative TLC was carried out on the same sample because of its relative low complexity as 
seen with TLC. Five UV active fractions were scraped off and eluted with acetone and 
methanol to ensure full recovery of the sample. Only the baseline material showed biological 
activity. Further investigations revealed that the baseline fraction contained many compounds, 
which were then separated using a chromatotron to obtain amounts that would be sufficient for 
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conducting a bioassay and characterisation using spectroscopic techniques like NMR 
spectroscopy. 
Problems encountered with column chromatography were not so much in the procedure 
involved but in the resulting fractions. Some fractions appeared to be more complex after 
passing through a column than they had been prior to separation. There was an increase in 
fractions eluted due to an increase in concentration of the solution applied to the TLC plate. 
Some Rf values of the fractions differed dramatically from the parent column. It might also be 
possible that decomposition had taken place and artefacts had formed which contributed to a 
more complex chromatogram. 
3.3.1.3 Chromatotron separation 
The ethyl acetate/methanol fractions with antimicrobial activity as seen with the bioassay were 
subsequently chosen for the separation via a chromatotron. It was decided to remove non-polar 
components with a solvent such as petroleum ether and another solvent; ethyl acetate was 
gradually introduced up to 100 %. This method achieved good separation. The third solvent 
methanol was added gradually to remove non-mobile components. Care was taken that the 
concentration of methanol did not increase above 50 % as it has tendency to dissolve silica 
gel, which subsequently interferes with the structural elucidation. 
3.3.2 Bioassay Monitoring 
There were basically two solvent systems used for the extraction of an antibacterial agent, 
namely petroleum ether and ethyl acetate. The petroleum ether was used for the extraction of 
non-polar substances like fatty acids. The bioassay tests were done so as to check if the 
extracted non-polar substances have any biological activity. The test organisms used were 
Pseudomonas fluoscens, which is a plant pathogen, and Serratia marcescens, which is a 
human pathogen. It could be clearly seen that the petroleum ether extract had no biological 
activity since no inhibition zones were observed around the disk papers (Figure 37). After 
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removing fatty acids, the ethyl acetate was then used so as to extract any organic polar 
compounds. The bioassay tests were done so as to check if the ethyl acetate extract had any 
biological activity. The test organisms used were similar to those used for petroleum ether 
extract. It was found that the antibacterial agent is a polar organic substance, since clear 
inhibition zones were observed around the disk papers see Figure 38. 
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Figure 37: Bioassay results for petroleum ether extract; test organism used was Serratia 
marcescens 
The ethyl acetate extract was found to consist of five different bands when viewed under 
ultraviolet light. Column chromatography was done so as to separate different bands. The 
solvent system used was ethyl acetate and petroleum ether (9: 1). Further purification was 
done using a chromatotron. Each band was tested for biological activity, and there was no 
biological activity in all these bands. In a thin-layer chromatography plate (TLC), there was a 
yellow spot observed at the baseline, this spot was extracted with a more polar solvent 
(methanol) and concentrated on the rotary evaporator. This methanol extract was checked on 
the TLC plate and it was found that there were four bands observed when viewed under 
ultraviolet light. These bands were polar because a mixture of two polar solvents (methanol 
and acetone) in a ratio of (3: 97) was used so as to move these bands from the baseline. It 
could be stated that there were more than four bands that constituted the lower spot. However, 
not all of these bands were ultraviolet active because they were not observed under ultraviolet 
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light of 254 nm, the extra bands were observed when the TLC was developed with 
anisaldehyde stain*. Further purification so as to separate the different components was done 
using a chromatotron. Each fraction collected was tested for biological activity and only one 
fraction showed biological activity, the purple spot fraction when viewed under ultraviolet 
light. After determining that the antibacterial activity was due to the purple spot fraction, 
further purification was done using preparative thin-layer chromatography. It was found that 
there were two other fractions that were closer to the purple spot fraction. The Rf for the 
purple spot fraction was 0.45 and there was a fraction above this with the Rf of 0.49 and the 
fraction below had an Rf value of 0.41. As a result the chromatotron was run so as to further 
separate these fractions. The pure fraction crystallized into yellow fluffy shiny crystals. 
Biological activity for this pure fraction was tested against Serratia marcescens, and 
Pseudomonas fluoscens and it was found that the isolated fraction was able to inhibit the 
growth of these test organisms (Figure 38). 
Figure 38: Agar plate showing biological activity of the purple spot fraction, test organism 
used is Pseudomonas fluoscens. 
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3.3.3 Structural elucidation of active compound by Nuclear Magnetic Resonance 
Spectroscopy (NMR) 
The application of NMR techniques is growing rapidly in the elucidation of the structure and 
function of biologically important molecules. In this section the role of NMR in determination 
of the structure of the active compound will be discussed. Apart from the H NMR and C 
NMR, other spectroscopic experiments such as DEPT, COSY, HMBC and HMQC were used 
for structural determination of the compound. 
3.3.3.1 'H NMR Spectrum 
The 'H NMR of the isolated compound showed that the compound has four protons resonating 
in the "aromatic" region. Four sets of proton signals observed include the Ha proton signal at 
7.94 ppm, a doublet of doublets with coupling constants of 8.1 Hz resulting from ortho 
coupling with Hb and meta coupling with Hc respectively (Figure 39). The low-field shift of 
Ha (5H 7.94) indicated that it must be ortho to a carbonyl-containing functional group. The 
shift to the lower field is caused by the anisotropic effect of the neighbouring carbonyl group. 
The Hc proton signal has a chemical shift of 7.32 and is a doublet of doublets of doublets, 
having a coupling constant of 8.1 Hz, where it ortho couples with Hd, and meta couples with 
Ha with a coupling constant of 0.7 Hz, and also ortho couples with Hb with a coupling constant 
of 7.0 Hz. Hd appeared as a doublet of doublets at 6.70 ppm, with coupling constants of 8.3 Hz 
and 0.7 Hz from ortho coupling with Hc, and meta coupling with Hb respectively. The signal 
of proton Hb appeared as a doublet of doublets of doublets at 6.66 ppm, with coupling 
constants of 8.1, 0.7 and 7.0 Hz from ortho coupling with Ha, meta coupling with Hd and ortho 
coupling with Hc respectively. 
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Figure 39: lHNMR Spectrum for isolated antibacterial agent. 
13 3.3.3.2 "C NMR Spectrum 
The 13C NMR spectrum showed seven carbons, one of which is a carbonyl and the rest are 
aromatic (Figure 40). In the isolated antibacterial agent there are four methine aromatic 
carbons at the chemical shifts (8c) equal to 116.5, 116.8, 132.1 and 135.1, respectively. Three 
non-protonated carbons at chemical shift (8c) 109.5, 151.1 and 173.2. Of all the non-
protonated carbons, C3 with the chemical shift of 109.5 is most upfield. Ct with a chemical 
shift of 173.2 appears most downfield, and is most likely a carboxylic acid. It could therefore 
be deduced that X in our compound is a carboxylic group. 
C, 
Figure 40: C NMR Spectrum for the isolated antibacterial agent 
73 
3.3.3.3 ^ H COSY 
The COSY (Correlation Spectroscopy) is a 2-Dimensioanal NMR spectrum that shows 
correlation between coupled protons. From the upper right to the lower left runs the diagonal, 
a series of absorptions in which vj equals V2, these diagonal peaks provide nothing in the way 
of useful information beyond the simple 1 -D H spectrum. On either side of the diagonal and 
symmetrical disposed are cross peaks. The structure of isolated compound allows more than 
one useful entry point. The methine (CH) at the chemical shift of 7.88 has been selected for 
illustration. If one begins at the diagonal and traces either directly to the right or directly up, 
the same result is obtained because the spectrum is symmetrical. Two off diagonals or cross 
peaks are intersected. At right angles to the ones just traced, the chemical shifts of the two-
coupled resonances can be obtained. A quick check at the structure of the isolated compound 
finds Ha adjacent to an ortho proton Hb and also meta proton Hc. Likewise Hb at the chemical 
shift if 6.6 ppm is ortho coupled to Hc and Ha and meta coupled to Hd-
On the other hand, if another equally useful entry point corresponding to Hc at 5H 7.2 is 
selected, again beginning at the diagonal, this time it can be found that Hc is correlated with 
three distinct resonances. It first correlates to Hb and Hd that are ortho to it. In addition, Hc is 
correlated to Ha doublet of doublets to the left of the diagonal. These correlations of course 
make perfect sense with the structure, and hence connectivities can be made. The COSY 
spectrum for the isolated antibacterial agent showed four signals, this agreed well with the 
proton spectrum. The information obtained from COSY spectrum helped in determining which 
proton is correlated to which one. From this spectrum it was then observed that Hd is 
correlating with Hb, and also true with correlating with Hb and Hc that are correlating with 
each other and also with both Ha and Hd. (Figure 41). 
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Figure 41 COSY spectrum for the antibacterial agent 
The HSQC and HMQC spectra were then used to show the single-range coupling and 
multiple-range coupling of protons and carbon respectively. The NMR spectra for the single-
range and multiple range couplings are shown in Figures 42 and 43 respectively. 
ITT 13 3.3.3.4 'H- C HMQC and HSQC 
The 'H-^C experiment correlates ' C nuclei with directly attached (that is coupled) protons; 
these are one-bond (!JCH) couplings. The frequency domains of Fi (vi) and F2 (v2) are of 
different nuclei, and so there is no apparent diagonal or symmetry. Historically, the HMQC 
(Heteronuclear Multiple Quantum Correlation) experiment was preceded by the HETCOR 
(HETeronuclear CORrelation) experiment. Although experimentally there are many 
differences, the essential difference is that, while the HETCOR experiment is carbon detected, 
the HMQC experiment is proton detected ' Since there are great differences between proton 
and carbon in their relative abundances and sensitivities, the HMQC is greatly preferred and 
the outcome of HSQC and HMQC experiments on the isolated antibacterial agent will be 
discussed below. In the HMQC spectrum, the proton scale is on the F2 axis along the y-
direction and the carbon-13 scale in on the Fi axis along the x-direction. Immediately obvious 
is the fact that there is no diagonal or symmetry. This is true because as mentioned above Fi 
and F2 represent different nuclei. Since the HSQC experiment provides the information about 
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correlation of protons with directly bonded carbons, so it could be seen from Figure 42, that 
proton Ha is bonded to C7, He bonded to C5, Hd bonded to C4 and Hb bonded to C6, 
respectively. 
ft 
Figure 42: HSQC spectrum for antibacterial agent. 
The same is true with the HMQC experiment that gives information about the correlation of 
protons with neighbouring carbons. From the results in Figure 43; one could observe the 
coupling between Ha and Ci, Haand C3 as well as Ha and C5. There is also a coupling between 
Hc and C7, and C3 respectively. The carbon-hydrogen coupling is also observed between Hb 
and C2, and Hb and C4. The last observed carbon-hydrogen coupling is between Hd and C2 and 
C5 respectively. All these couplings are three bond couplings and are stronger than the one and 
two bond coupling. Since the compound is aromatic, one could also observe the four-bond 
coupling though this is a rare case which occurs in aromatic systems. 
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Figure 43: HMQC Spectrum for antibacterial agent. 
Interpretation of this spectrum is straightforward. One begins at any carbon atom and mentally 
draws a line horizontally until a cross peak is encountered. Another line is mentally drawn 
perpendicular to the first to find the proton or protons with which it correlates. There are only 
three cases possible for each carbon atom. If a line drawn encounters no cross peaks, then the 
carbon has no attached hydrogens. If the drawn line encounters only one cross peak, then the 
carbon may have 1, 2 or 3 protons attached. If two protons are attached, they are either 
chemical shift equivalent or they overlap. If the line encounters two peaks, there is a special 
case of diastereotropic protons attached to methylene group. Much of this information is 
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confirmed by the DEPT spectrum (Figure 44), which shows the presence of -CH3, -CH2 and 
-CH groups. In the case the compound, only the presence of -CH groups is shown by the 
DEPT spectrum. Therefore, the HMQC spectrum should, whenever possible, be considered 
along with the DEPT spectrum. 
Figure 44: DEPT Spectrum for the isolated antibacterial agent. 
3.3.3.5 Infra Red Spectroscopy (IR) 
The infrared spectroscopy was used to identify the functional groups present in the structure. It 
was deduced that our compound displays a strong broad -NH2 stretching absorptions in the 
3474 and 3374 cm"1 region, due to the symmetrical and unsymmetrical -NH2 stretching. The 
very strong and broad OH stretching absorption that extends from 2500 to 3300 cm"1 shows 
the presence of the carboxylic acid functionality (Figure 45) 
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Figure 45: Infrared spectrum for the isolated antibacterial agent. 
This further suggests that the compound exists predominantly as a hydrogen bonded dimmer. 
The carbonyl stretching frequency for this dimer is found at the wavenumber of 1672 cm" . 
The bands that appear between 2000 and 1667 cm"] are due to the aromatic overtones and 
combinations. These weak absorptions can be used to assign the ring substitution pattern, 
whether mono-, di- or tri- substitution pattern and as shown in Figure 46 positional isomers 
can also be distinguished.69 Usually, if there is a carbonyl group present, the frequency due to 
that carbonyl can disturb the overtone pattern. Fortunately, the carbonyl stretching frequency 
appears slightly lower than this region and had no effect on the pattern. 
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Figure 46: Different regions for different substitutions on the aromatic ring 
When looking at the infrared spectrum of the compound, it could be noted that its overtone 
region is similar to that of or^o-substitution Figures 45 and 46. By using all of the above 
information, the antibacterial agent was found to be anthranilic acid. 
3.3.3.6 Mass Spectrometry 
There are three basic functions that the mass spectrometer performs. It firstly subjects the 
molecules to the bombardment by a stream of high-energy electrons, whereby the molecule is 
converted to ions by high-energy electrons. These ions then get accelerated towards the 
electric field. Different fragments are then detected by the mass spectrometer. From the mass 
spectrometer results one could observe six different fragments with high intensities. 
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Figure 47: Low resolution mass spectrum for anthranilic acid. 
Taking into account the NMR and IR spectroscopic data, a molecular formula of C7H7NO2 
could be elucidated for the molecule and it is clear that anthranilic acid can account for all the 
data. 
On the mass spectrum (Figure 47), the base peak appears at m/z 137. It has an odd mass due 
to the presence of one nitrogen atom in the molecule. In the Ms spectrum a second peak 
appears at m/z 119 that corresponds to the loss of water from the anthranilic acid structure as 
shown in (Scheme 11). The third fragment with m/z of 92 corresponds to the decarboxylation 
of anthranilic acid as shown in Scheme 12. 
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Scheme 12: Fragmentation of anthranilic acid by loss ofcarboxyl group. 
In addition to the low-resolution mass spectrum of anthranilic acid, the high-resolution mass 
spectrum was obtained and is shown in Figure 48. The calculated mass of anthranilic acid 
(C7H7O2N) was 137.04768 and experimentally determined to be 137.04609. 
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Figure 48: High-resolution mass spectrum for anthranilic acid. 
3.3.3.7 X-ray studies of anthranilic acid 
The structure of anthranilic acid was confirmed by x-ray crystallography and was found to be 
in the orthorhombic space group Pbca. The dimensions of the unit cell were found to be a -
7.106(2) k,b= 15.835(4) A, c = 11.641(3) A, a = 90°, B = 90°, y = 90° Volume 1309.8(6) 
A^ The crystallographic structure of anthranilic acid is shown in Figure 49. 
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Figure 49: ORTEP drawing of anthranilic acid with thermal ellipsoid plot (50% probability 
surfaces) 
Further crystal structure data for anthranilic acid is contained in the appendix. One of the 
features of the crystal structure is that there are eight molecules in the symmetric unit as 
shown in Figure SO. 
Figure 50: Unit cell contents viewed approximately down the a-axis. 
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Figure 51: Hydrogen bonding between molecules of anthranilic acid in the lattice. 
There are several hydrogen bonds and % - n stacking interactions between the molecules in the 
crystal structure as shown in Figure 51 and 52. The hydrogen bonds observed are: 
• Discrete carboxylic acid dimers are evident. Both carboxylates are bound 
symmetrically to each other with a hydrogen bonding of 1.641 A. 
• Weak intramolecular N-H—O interactions with a distance of 1.944 A. 
• The dimers interact through weaker non-stereospecific intermolecular N-H—O 
interaction with the distance of 2.260 A. 
Brown, using X-rays7 and later using neutron diffraction,71 showed the novel coexistence of 
neutral molecules and zwitterions in the same crystal of anthranilic acid as shown in 
Figure 53. Contrary to these findings, In this project no evidence of the formation of 
zwitterions was found. The centre-to-centre phenyl ring stacking interaction has a distance of 
3.278 A as shown in Figure 52. The anthranilic acid dimers lay in parallel sheets that are all 
fairly planar. It is therefore concluded that in the solid state, these hydrogen bonds and TC -n 
stacking stabilise anthranilic acid. However, It is suspected that x-ray crystallography of 
anthranilic acid isolated by precipitation would have zwitterions. Some attempts to grow a 
suitable crystal to run x-ray crystallography from the precipitated anthranilic acid was not 
successful; therefore, the speculation presented in the preceding sentence could not be tested. 
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Figure 52: The anthranilic acid dimers lay in parallel sheets that are all fairly planar. 
Figure 53: Evidence of the formation of zwitterions from studies by Brown, 71 
3.3.4 Acid-Base extraction 
A common and important use of extraction is the separation of acidic, basic and neutral 
organic compounds. An organic acid, RCO2H, or a base, such as RNH2, is usually much more 
soluble in organic solvents than in water. However, the salts of these compounds, for example 
RC02"Na+ or RNH3
+C1", have much higher solubilities in water, since they are ionic 
substances. To separate an acid, for example, the broth was basified with sodium hydroxide 
and extracted with ethyl acetate to remove basic and neutral entities. Following the isolation 
procedure outlined in Figure 54, the acid was converted to the salt (Equation 1). After 
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separation of the broth and ethyl acetate, the acid was recovered by reacidification of the 
aqueous solution (Equation 2). 
RC02H + NaOH RC02"Na
+ + H20 (l) 
RC02Na
++ HCl *" RC02H + Na
+Cl" (2) 
The acidic component was then extracted with ethyl acetate and this sample was analysed by 
gas chromatography. By the same principle, the basic component was separated from acidic 
and neutral compounds by acidifying the broth with aqueous acid, (in this experiment 2 N HCl 
(Equation 2) was used). After removal of acidic and neutral entities with ethyl acetate, the 
solution was basified by adding NaOH (equation 4), and then extracted with ethyl acetate. 
RNH2 + HCl -RNH3
+C1- (3) 
RNH3C1 + NaOH ^ R N H 2 + H20 + NaCl (4) 
The ethyl acetate extract was also analysed by gas chromatography. The third procedure 
followed was that the broth was simply extracted with ethyl acetate. All three extracts were 
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Figure 54: General outline for the separation of acidic, basic, and neutral components of a 
mixture 
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When looking at the chromatogram in Figure 55, it is clear that the peak corresponding to the 
anthranilic acid is only observed in the neutral extract. This means that anthranilic acid is 
neither an acid nor a base because if it was an acid it would have been present in the acid 
extract and same is true for basic extract. This agrees well with the low yield that was obtained 
when conducting solvent to solvent extraction of the fermentation broth, and isolating 
anthranilic acid was not easy. As a result, further experiments were conducted to find the best 
method of increasing the yield of anthranilic acid and shortening the procedure involved in the 
isolation of anthranilic acid. 
Figure 55: Gas chromatogram of anthranilic acid (commercially available), acidic, basic 
and neutral components. 
3.3.5 Electrophoresis 
O'Farell and Klose first introduced two-dimensional electrophoresis in 1975.73'74 This is a 
powerful and widely used technique for the analysis of complex protein mixtures extracted 
from cells, tissues or other biological samples. This method separates proteins according to 
two independent properties in two discrete steps, namely the first-dimension step, isoelectric 
focusing (1EF), which separates proteins according to their isoelectric point (pi) and the 
second-dimension step, SDS-polyacryamide gel electrophoresis (SDS-PAGE), which 
separates proteins according to their molecular masses. In the work carried out in this study, 
the isolation of the bacteriostatic agent (anthranilic acid) had been achieved by solvent-solvent 
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extraction. The yield of this procedure was very low and the product required many 
chromatographic separations to determine the pure compound. It was therefore necessary to 
optimise the isolation procedure by making sure that there were fewer isolation steps and the 
yield was improved. 
Isoelectric focusing (IEF) can be described as electrophoresis in a pH gradient set up between 
a cathode and anode with the cathode at a higher pH than the anode, and is one of the most 
discerning separating methods based upon the gross physical properties such as charge or 
size.75'76 Proteins are amphoteric molecules; they carry either positive, negative or zero net 
charge, depending on the pH of the solvent. The net charge of a protein is the sum of all the 
negative and positive charges of its amino acid side chains including the amino and carboxyl-
termini. The isoelectric point (pi) is the specific pH at which the net charge of protein is zero. 
Proteins are positively charged at pH values below their pi and negatively charged at pH 
above their pi. When the electrical potential is applied across the gradient, the pH gradient is 
established by the carrier ampholytes, and the protein species migrate and focus at their 
isoelectric points. In this manner a mixture of proteins is separated, as each focuses at different 
pi as shown in Figure 56. 
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Figure 56: Separation of an amino acid mixture by electrophoresis, neutral molecules do not 
migrate, protonated molecules migrate toward the negative electrode and 
deprotonated molecules toward the positive electrode. 
In this work 2-D electrophoresis has been employed, and the anthranilic acid is separated in 
the first dimension according to its isoelectric point and in the second dimension, according to 
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its molecular mass by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE).77 In the present case the second dimension of anthranilic acid was not determined, 
since the interest was only in its pH and not in its molecular mass. As result the isoelectric 
point of anthranilic acid was found to be 8.25 (see Table 4). 
Since anthranilic acid has both carboxyl and the amino functional groups, it was assumed that 
it would behave as a neutral amino acid. The amino acids that have both acidic and basic 
groups in the same molecule undergo an intramolecular acid-base reaction and exist primarily 
in the form of a dipolar ion or zwitterions. In acid solution (low pH) amino acids become 
protonated and thus exist as cations, and in basic solution (high pH), they exist as anions. The 
intermediate step where an amino acid is balanced by the anionic and a cationic form is called 
the isoelectric point, and that is where it exists as dipolar ions. 
It has been reported from the literature that all neutral amino acids have isoelectric points in 
the pH range of 5.0-6.5 and not exactly 7.0 as one might expect.5 This is caused by the fact 
that carboxyl groups are stronger acids in aqueous solution than amino groups and as a result 
they tend to dominate. For example, amino acids with acidic side chains (for example aspartic 
acid) as shown in Table 4 have isoelectric points at lower or more acidic pH to suppress the 
dissociation of the extra carboxylate group in the same side, while amino acids with basic side 
chain (for example histidine) also shown in Table 4 have isoelectric points at higher or more 
basic pH to restrain protonation of the extra amino group. 
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Table 4: Structures of amino acids and their isoelectric points 
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Anthranilic acid 8.25 
COOH 
NIC 
Anthranilic acid as a neutral molecule was expected to behave like neutral aromatic amino 
acids, such as phenylalanine and tyrosine with the isoelectric points of 5.5 and 5.7 
respectively. However, the isoelectric point found experimentally for anthranilic acid is 8.25. 
It is proposed that anthranilic acid has this unusually high isoelectric point because its 
protonated form is very stable, since the cationic charge on the nitrogen atom can be stabilised 
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Scheme 13: Mesomeric effect in anthranilic acid 
3.3.6 Isolation of anthranilic acid by precipitation 
Having determined that the anthranilic acid displayed neither acidic nor basic properties, it 
was then believed that the anthranilic acid behaved like a neutral amino acid. The 
electrophoresis for the anthranilic acid was then done so as to determine the pH at which it 
precipitates from solution. The pH at which anthranilic acid precipitated was found to be 8.25. 
The nutrient broth was then adjusted to the pH of 8.25, and a small amount of precipitate was 
formed. This was filtered; dried in an oven and dissolved in ethyl acetate and the gas 
chromatography results are shown in Figure 57. The gas chromatogram of the precipitate and 
that of the commercially available anthranilic acid match with each other, and both have a 






1 [ 7.5 10.0 12.5 15.0 




3.4 Fate of anthranilic acid 
From the work done it is not clear whether the anthranilic acid isolated was the end product, 
biodegradation product or a precursor leading to some other secondary metabolites. The 
literature has many examples of the three scenarios and each case will be considered below. 
3.4.1 Anthranilic acid as a precursor 
It has been reported in the literature that anthranilic acid has been used as a precursor in the 
synthesis of different compounds including anthranilohydrazide, 3,4-dihydro-4-oxo-l; 
2,3-benzotriazine, triazine-(3-naphthol adduct and n-phenylanthranilic acid. These compounds 
showed antibacterial activity but none of the compounds showed any noticeable antifungal 
effect.79 For instance, Hurley and co-workers accounted for the feeding of antitumor 
antibiotics produced by various Actinomycetes, which are anfhramycin, tomaymycin, and 
sibiromycin with anthranilic acid, 3-hydroxy-4-methylanthranilic acid and tryptophan. The 
results are shown in Table 5. From these results, it could be clearly seen that anthranilic acid 
was efficiently incorporated into tomaymycin, but this was almost certainly via tryptophan, 
since the incorporation into tomaymycin was reduced by greater than 80% when cold 
tryptophan was added in a parallel feeding experiment. Anthranilic acid and 3-hydroxy-4-
mefhylanthranilic acid were not successfully taken up by the anthramycin and as a result their 
precursor role was not properly measured. But anthranilic acid was effectively taken up by 
sibiromycin. However, 3-hydroxy-4-methylanthranilic acid was incorporated into 
sibiromycin. 
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Table 5: Incorporation of labelled substrates into anthramycin, tomaymycin and 
sibiromycin 22 
Compound fed 
Percentage incorporation into: 













<0.1a NE 14.1 
DL-[7a-14C] tryptophan 18.0 4.0 
a Radiolabeled substrates failed to be taken up significantly by the organism, 
b Parallel feeding experiments in which a 100-ml culture of S.achromogenes 
was divided into halves prior to the addition of [COOH-14C]anthranilic acid 
to each flask and DL-tryptophan to one of the two flasks. 
NE, not examined 
3.4.1.1 Shikimic Acid Pathway 
Shikimic acid is an organic acid, which was first isolated from the fruits of Illicium species, 
o i 
where it was present in large quantities (up to 20 %) . The name shikimate was derived from 
Japanese name for the tree Murium religiosum, shikimi-no-ki (anise tree). About 60 years 
later it was revealed that shikimate was an intermediate in the aromatic amino acids 
biosynthesis in plants and microorganisms, since animals cannot carry out de novo synthesis 
of aromatic amino acids. Scheme 13 shows the shikimic acid pathways. There are seven 
enzymes of the shikimate pathway that catalyse sequential conversion of erythro-4-phosphate 
and phosphoenol pyruvate to chorismate, which is used as a substrate for other pathways that 
culminate in the production of folates, ubiquinones, naphthoquinones and the aromatic amino 
acids tryptophan, phenylalanine and tyrosine as shown in Scheme 14 and Scheme 15.83 
4-Aminobenzoate and 4-hydroxybenzoate, the precursors of tetrahydrofolate and benzo-and 
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naphthoquinones, respectively, are directly biosynthesised from chorismate. Menaquinone, 
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Scheme 14: Chorismate and beyond primary metabolism pathways. 
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An interesting group of secondary metabolites containing aromatic rings is derived from 
intermediates of aromatic amino acid biosynthesis or the aromatic acids themselves 
(Scheme 15). Many of these compounds are clinically important, especially vancomycin and 
teicoplanin. These glycopeptide antibiotics are active against methicillin resistant 
Staphylococcus aureus (MRSA). 
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3.4.1.2 Alkaloids biosynthesised from Anthranilic acid 
All of the antibiotics featured in Scheme 15 are alkaloids. Alkaloids belong to an important 
class of natural products, which are nitrogenous compounds occurring in plants, toads and 
animals including mammalian and fungi. Most of them are optically active, and nearly all of 



































Figure 59: Diagram showing anthranilic acid-derived antibiotics 
99 
Among the commonly known naturally occurring alkaloids, benzodiazepines form a class of 
biologically active compounds from which widely prescribed psychoactive drugs have been 
developed.88 These compounds also have potential as highly selective anti-infective agents.89 
To date, about thirteen members of well-known antibiotics are produced by various 
Streptomyces species. These include anthramycin (101), and tomaymycin (102), abbeymycin 
(103), chicamycin (A) (104), DC-81 (105), mazethramycin (106), sibanomicin (DC-102) 
(107), sibiromycin (108) and prothracarcin (109) (Figure 59). Hurley90 has studied the 
biosynthesis of a number of these compounds; they all have anthranilic acid as a precursor. 
The anthranilic acid nucleus has been highlighted. 
3.4.1.3 Biosynthesis of Enediyne Antitumor Antibiotics 




Figure 60: Structure of an enediyne antibiotic. 
Enediyne antibiotics (Figure 60) are potent antitumor agents. Although natural enediynes 
have seen limited use as clinical drugs mainly because of substantial toxicity, various 
polymer-based delivery systems or enediyne-antibody conjugates have shown clinical promise 
and success in anticancer chemotherapy. A great challenge will be to develop ways to make 
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new enediynes for mechanistic and clinical studies. A closer look at the enediynes reveals an 
anthrinilic acid nucleus as shown in Figure 60. Anthranilic acid is used as a precursor; the 
structural analogues of enediyne could be obtained by feeding Streptomyces globisporus with 
analogues of anthranilic acid. 
3.4.1.4 Biosynthesis of 2-heptyl-3-hydroxy-4-quinolone from 
anthranilic acid 
Through 14C labelling studies, Pesci et al.91 found that anthranilate is a precursor of the 
production of 2-heptyl-3-hydroxy-4-quinolone (112) (Figure 61); it is referred to as the 
















Figure 61: Biosynthesis of 2-heptyl-3-hydroxy-4-quinolone from anthranilic acid. 
However, methyl anthranilate was found to inhibit the production of PQS, and could be used 
in the development of therapeutic agents that will reduce the effectiveness of Pseudomonas 
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aeruginosa. 
3.4.2 Anthranilic acid as a metabolic degradation product 
It has been reported in the literature that anthranilic acid could be formed as a product of 
catabolism, for instance some strains of Bradyrhizobium japanicum have the ability to 
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Scheme 16: Catabolism of indole-3-acetic acid to anthranilic acid 
Furthermore, anthranilic acid can be obtained as the metabolic end product of the kynurenine 
pathway of tryptophan (Scheme 17). The other end product of this pathway is the neurotoxin 
quinolic acid, which is responsible for the neuronal cell death in a number of important 
neurological diseases. As a result this makes kynureninase a possible therapeutic target for 
diseases such as Huntington's, Alzheimer's and AIDS related dementia.94 This is an enzyme-
catalysed reaction, and the enzyme involved in catalysis is kynureninase. 
C02H 




Scheme 17: Formation of anthranilic acid from kynureninase pathway of tryptophan. 
3.4.3 Anthranilic acid as a secondary metabolite 
Anthranilic acid also known as vitamin Li can exist as a secondary metabolite; which is 
required for lactation in human females ' . Bovine liver and also Aloe vera products are rich 
sources of vitamin Lj. Anthranilic acid is the ortho-isomer of/rara-aminobenzoic acid 
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(PABA), which is widely used as the active inhibitor of the bacteriostasis produced by the 
sulfonylamide drugs. It is also used as the growth factor for several species of bacteria 
including Neurospora crassa?1 PABA is an essential metabolite for bacteria that is involved 
in the biosynthesis of folic acid that is necessary for the growth of bacteria and is therefore 
widely distributed in nature. The sulfonamides have chemical structures similar to that of 
PABA, and may act as bacteriostatic agents by competing for the bacterial enzyme concerned 
with the metabolism of PABA.98 Unlike anthranilic acid, PABA has been isolated from yeast 
by Rubbo and Blanchard.9 ' Anthranilic acid, however, is an aromatic amine which occurs 
physiologically as a metabolite of the amino acid tryptophan and may be further broken down 
into carbon dioxide, water and ammonia. 
3.5 Conclusion 
The aim of this project was to isolate and characterise the antibacterial agent produced by 
Actenomycete bacterium V3. The extraction and characterisation as well as isolation was 
successfully achieved. Much was learnt during this process about the behaviour of 
microorganisms and the use of aseptic techniques. Different extraction procedures were 
successfully accomplished. A crystal structure was obtained to conclusively prove the 
structure of the isolated antibacterial agent as anthranilic acid, also known as ortho-
aminobenzoic acid. 
The solvent-to-solvent extraction procedure was first used for the extraction of the 
antibacterial agent. Due to the low yield obtained, lengthy steps involved and large volumes of 
solvent used in the solvent-to-solvent extraction, the method was improved by the use of an 
acid-base extraction process. At this time the extraction of the antibacterial agent was not 
successful. It was therefore deduced that the isolated compound is neither a base nor an acid. 
The electrophoresis experiment was carried out so as to determine the pH of the isolated 
compound. It was then assumed that this compound behave like an amino acid. The pi at 
which the anthranilic acid precipitate out of the solution was found to be 8.25, and the 
compound precipitated out of solution. 
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Gas chromatography of this precipitate was compared to that of the commercially available 
anthranilic acid, and it was found that both these compounds eluted at the same time. It was 
therefore concluded that the faster and effective method for isolating the antibacterial agent 
produced by soil bacterium V3 is by precipitation. 
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4. Experimental 
4.1 Materials and Methods 
4.1.1 General Experimental Procedures 
Flash column chromatography was carried out using Merck silica gel 60 as a solid support in 
accordance with literature procedure. The crude material was either preadsorbed onto the 
column support or applied as a concentrated solution on top of the column. The columns were 
then eluted with various ratios of ethyl acetate (b.p 40-60 °C) in petroleum ether. 
Thin-layer chromatography (TLC) was performed on precoated Merck Kieselgel 60 F254 
plastic sheets. TLC plates were used for monitoring separations in both column 
chromatography and chromatotron and also as a separation technique. Visualisation of the 
plates was achieved using the following techniques: 
• Fluorescence on exposure to ultraviolet light (254 nm). 
• Developing by dipping them in an anisaldehyde stain. The anisaldehyde stain was 
prepared whilst cooling the reagents in nitrogen by adding 5 ml of glacial acetic acid, 
17 ml of concentrated sulfuric acid, 13 ml /7-anisaldehyde in 465 ml of absolute 
ethanol. The dipped TLC plate was heated with a heat gun. 
• Developing in an aqueous cerium sulphate (0.2%), ammonium molybdate (5%) and 
sulphuric acid (5%) solution followed by heating with a heat gun. 
• Developing in an aqueous potassium permanganate (0.5%) and sodium hydrogen 
carbonate (2.5%) solution and drying. 
Further purification of compounds was achieved by using the Harrison research 
chromatroton or preparative TLC plates. Preparative TLC plates were prepared on baked 
glass plates (12 cm x 20 cm x 20 cm) coated with silica gel. The Silica gel (Merck 
Kieselgel 60 F254) (200 g) was homogeneously suspended in distilled water (500 ml). This 
paste was rapidly spread on cleansed grease-free glass plates with a spreader. These plates 
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were kept in a draft free place for 48 hours at room temperature and subsequently activated 
for 48 hours at 120 °C. 
NMR spectra were recorded on a Varian Unity Inova 500 spectrometer at 25°C using 
deuterated chloroform as solvent and residual protonated solvent as the internal standard. The 
chemical shifts are reported in parts per million (ppm, 5) and the coupling constants in Hertz 
(Hz). 
Infrared spectra were obtained on a Perkin Elmer one spectrometer as films on KBR discs. 
The mass spectra were recorded on a ThermoFinnigan Polaris / QCQ Plus instrument coupled 
to a Varian CP-3800 gas chromatograph. Low and high resolution mass spectra were 
measured on a Kratos MS 80 RF double-focussing magnetic sector instrument at 70 eV. 
Spectra were obtained using the electron impact mode (EI) and chemical ionisation mode (CI). 
Melting points were determined using a Kofler hot-stage apparatus by placing a few crystals 
on a dish and is uncorrected. 
X-ray diffraction studies were performed on an Oxford Diffraction Xcalibur 2 CCD 4-circle 
Diffractometer equipped with an Oxford Instruments Cryojet. 
Autoclaving was accomplished by using a Vertical type model HL-341; Aseptic techniques 
were all performed on a Julian ward laminar bench. The bacterial growth curve was 
determined on a Milton Roy Spectronic spectrophotometer at the wavelength of 550 nm. 
Centrifuging was achieved on a 8 tube continuous flow centrifuge (Szent-Gyrgyi Blum, KBS-
3, Sorvall type SS-3). 
Electrophoresis was done on a Pharmacia Biotech instrument using a 3-10 pi, 110 mm strip 
from Amersham Scientific, and an immobiline dry strip reswelling tray from Pharmacia 
Biotech. 
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4.2 Microbiological Materials and Methods 
4.2.1. Microorganisms 
The organism (V3) used was obtained from Vincent Okudoh (PhD student from the 
department of Microbiology and Plant Pathology) at University of KwaZulu-Natal 
Pietermaritzburg campus. This microbe was reported to have antibiotic properties by Mr 
Okudoh in his MSc thesis. The test organisms used to evaluate the antibiotic properties for 
V3 are Staphylococcus aureus, Escherichia coli, Streptococcus faecalis, Serratia marcescens 
and Pseudomonas fluoscens. 
4.2.2 Storage and growth on agar 
The organism (V3) used was preserved as a frozen culture. For maintenance on agar slants, the 
bacterium was grown on a medium consisting of beef extract (0.2 g); acid hydrolysate of 
casein (1.7 g), starch (0.15 g), in 100 ml of water and the final pH for this medium was 
adjusted to 7.3. The stock cultures were maintained in two ways: 
• Mature slopes were stored in the refrigerator at 4 °C and working slopes sub-
cultured from them as required. 
• The mycelium from mature slope were taken up in a sterile solution of 20 % w/v 
glycerol in water and stored in 1.5 ml sterile vials at -196 °C. 
• The defrosted spore (mentioned above) suspensions were transferred to each slope 
of agar slants when necessary. 
4.2.3 Mueller-Hinton Agar 
This is a general-purpose medium suitable for the growth of a wide variety of microorganisms. 
It is composed of beef extract (2.0 g/L); acid hydrolysate of casein (17 g/L), starch (1.5 g/L), 
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agar (17 g/L) and the final pH for this medium was adjusted to 7.3 +/- 0.1 at 25°C. 
Mueller-Hinton agar was prepared by dissolving 38 g of medium in one litre of distilled water. 
This was heated with frequent agitation for one minute to completely dissolve the medium. 
Autoclaving at 121°C for 15 minutes was performed, and the medium was cooled to about 
40°C and then poured into petri dishes. Poured agar was allowed to cool and solidify before 
use. 
4.2.4 Nutrient Broth 
The nutrient broth is composed of meat extract (1.0 g/L), yeast (2.0 g/L), peptone (5.0 g/L) 
and sodium chloride (8.0 g/L). Preparation procedure involved dissolving 16 g of nutrient 
broth in 1000 ml of distilled water, followed by heating with frequent agitation to completely 
dissolve the medium and autoclaving at 121 °C for 15 minutes. The medium was cooled and 
the V3 bacterium was inoculated into this medium. This medium served as food for the 
bacteria. This was then incubated for fourteen days on a rotary shaker at 30 °C and 150 rpm. 
4.2.4.1 Seed Cultures 
A culture medium consisting of meat extract (1.0 g), yeast (2.0 g), peptone (5.0 g) and sodium 
chloride 8.0 g. in 1000 ml distilled water was prepared. The medium (100 ml) in 250 ml 
conical flask was inoculated and incubated for 2 days on a rotary shaker at 30°C and 150 rpm. 
4.2.4.2 Production of Cultures 
For the production of cultures, a medium consisting of meat extract (1.0 g), yeast (2.0 g), 
peptone (5.0 g) and sodium chloride (8.0 g) in 1000 ml distilled water was prepared. The 
medium (100 ml) in 250 ml conical flasks was inoculated with the seed culture (7.5 ml) and 
incubated for 14 days at 30°C and 150 rpm. 
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4.3 Interpolation of (V3) growth curve 
V3 culture was inoculated into the nutrient broth growth medium (100 ml). This broth was 
then shaken in a 30°C water bath for 48 hours. Aliquots (5.0 ml) of the broth were taken every 
30 minutes and the absorbance was measured at 550 nm using the spectrometer. The 
remaining sample was stored in a refrigerator to stop further growth. This residual sample was 
going to be used for further bioassay analysis. The results of this study are shown in Table 6 
and are represented graphically in Figure 34. 
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4.4 Isolation of an antibacterial agent, anthranilic acid, using solvent extraction and 
chromatographic techniques. 
The bacterial extract was prepared by inoculating 12 L of nutrient broth with V3 Sample, 
which was seeded for 48 hours. The inoculated broth was shaken for 336 hours at 37°C. Fatty 
acids were removed using a non-polar solvent, petroleum ether, and ethyl acetate was used for 
extracting other organic compounds. A ratio of 1:1 for solvent and nutrient broth was used and 
this was washed three times and the concentrated extracts were tested for antibacterial activity. 
The whole procedure used for extraction of a bacteriostatic agent is illustrated in Chapter 3, 
Figure 36. 
Inoculated nutrient broth (250 ml) was extracted with petroleum ether (5 x 100 ml) to remove 
fatty acids. Thereafter, ethyl acetate (5 x 100 ml) was used to extract the organic material from 
the broth. The organic layer was then dried with anhydrous MgS04, filtered and evaporated in 
a rotary evaporator, which resulted in a yellow liquid. Preparative thin-layer chromatography, 
using multiple elutions with 10 % petroleum ether in ethyl acetate afforded four separate 
bands. Elution of these bands plus the material on the baseline yielded five fractions. The 
material on the baseline was extracted with methanol. The fractions were tested for biological 
activity. 
When spotted on the TLC plate, the baseline fraction showed three compounds that were 
separated with the chromatroton. Further purification of the active fraction was achieved by 
using preparative chromatography using 5 % methanol in ethyl acetate, and this resulted in the 
isolation of a yellow solid anthranilic acid, which showed activity against Serratia marscences 
and Pseudomonas fluoscens (0.028 g/L, 0.30 %), mp: (140-145°C, lit104 144-148°C); 8H (500 
MHz, CDCI3): 7.94 (dd, 1H, 8.1 Hz, 1.7 Hz, Ha) 7.32 (ddd, 1H, 8.1 Hz, 0.7 Hz, 7.0 Hz, Hc), 
6.70 (dd, 1H, 8.3 Hz, 0.7 Hz, Hd), 6.66 (ddd, 1H, 8.1 Hz, .0.7 Hz, 7.0 Hz, Hb); §c (500 MHz, 
CDCI3): 109.5 (C2), 116.5 (C4), 116.8 (C6), 132.1 (C7), 135.1 (C5), 151.1 (C3), and 173.2 (Ci); 
m/z (EI): 137 ([M]+, 100 %), 119 (C7H5NO, loss H20, 63), 92 (C5H6N, loss C02 and H
+, 81), 
65 (38), 52 (12), 39 (24), HRMS: [M]+ 137.04768 C7H7N02 requires 137.04609; vmax (cm"
1): 
3400 (s, NH2), 3300 (s, OH), 1660 (s, CO) 
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Crystal structure determination of anthranilic acid. A yellow-needle shaped crystal was 
grown by slow evaporation of a saturated ethyl acetate. The general data collected and used 
for structural determination is described in Tables 6, 7 and 8. All the crystallographic data was 
analysed and solved by Professor O.Q. Munro of this department. The following information 
was obtained from the crystallographic data, C7H7NO2, fw =137.14, a = 7.106(2) k,b = 
15.835(4) A, c = 11.641(3) A, p= 90°, V=l309.8(6) A3, monoclinic, Z =8, Dc= 1.391 Mg/m
3> 
H =0.103 Mg/m3, T = 100(2) K, R 1 = 0.0669, wR2 = 0.1311 
4.5 Purification of bacteriostatic agent using thin-layer chromatography (TLC) 
Different ratios of solvent systems were used to find the best solvent system to use for 
preparative TLC separation technique. These were 30:70, 50:50 and 70:30 ethyl acetate to 
petroleum ether, and it was found that the one that gave clear separation was 90:10 ethyl 
acetate to petroleum ether. On the TLC plate, four fractions were observed. Another fraction 
was at the baseline. All the other fractions were tested for biological activity. The one at 
baseline was washed with methanol and concentrated by the rotary evaporator. When spotted 
on the TLC plate, it showed three compounds that were separated by chromatroton using 5% 
methanol in ethyl acetate. Further purification was achieved by using preparative 
chromatography. 
4.6 Electrophoresis 
To perform an isoelectric focusing (IEF) analysis, anthranilic acid was applied to a 
polyacrylamide gel and current was applied. The anthranilic acid was focused on an 
Immobilon 3-10 pH ready strip (Amersham Biosciences) overnight, for 16 hrs and 200 ul of a 
0.08021 M was loaded onto the gel. The electrophoresis was done by Dr Mervyn Beukes and 
the results are shown in Figure 62. The anthranilic acid migrated according to charge density 
until it reached that part of the gel with a pH corresponding to its pi. At this point, net charge 
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Figure 62: The photograph of anthranilic acid appearing on a polyacrylamide gel strip after 
electrophoresis as viewed under ultraviolet light at 254 nm. 
4.7 Isolation of bacteriostatic agent by precipitation 
The bacterial extract was prepared by inoculating nutrient broth (100 ml) with V3 Sample, 
which was seeded for 48 h. The inoculated broth was shaken for 336 h at 37 °C. The pH of 
the resulting broth was adjusted to 8.3 by adding NaOH. The product precipated out of 
solution and was filtered and dried to give white crystals of anthranilic acid (1.2 g. 1.2 %); 
mp: (140-145 °C, lit104 144-148); 8H (500 MHz, CDC13): 7.94 (dd, 1H, 8.1 Hz, 1.7 Hz, Ha) 
7.32 (ddd, 1H, 8.1 Hz, 0.7 Hz, 7.0 Hz, Hc), 6.70 (dd, 1H, 8.3 Hz, 0.7 Hz, Hd), 6.66 (ddd, 1H, 
8.1Hz, 0.7Hz, 7.0 Hz, Hb). 
4.8 Antibiotic screening test 
The agar diffusion method was used. In this method the agar was poured into a petri dish 
seeded with a test microorganism used for antibiotic screening. Paper discs were dipped into a 
extract of test compound After drying, these discs were placed onto the seeded agar and the 
compound was allowed to diffuse. For instance, the petroleum ether extract was concentrated 
on paper discs and allowed to diffuse into the agar containing the microorganism for 14 days 
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and the results are shown in Figure 63. No inhibition zones were observed; therefore the 
petroleum ether extract contained none of the antimicrobial active agents. On the other hand 
when the ethyl acetate extract was concentrated on the paper discs and placed on the agar 
containing the microorganism, after 14 days as shown in Figure 64, an inhibition zone was 
observed. 
Figure 63: Paper discs saturated with petroleum ether extract on Pseudomonas fluoscens. 
: 




1 Butler, M. S., Nat. Prod. Rep., 2005, 22, 162. 
2 Strohl, W. R., DDr, 2000, 5, 39. 
3 Ruegger, A., Kuln, M., Lichti, H., Loosli, H. R., Huguenini, R., Quiquerez, C , Von 
Wartburg, A., Helv. Chim. Acta, 1976, 59, 1075. 
4 Wall, E., Wari, M. C, Cancer Res., 1995, 55, 753. 
5 Brown, A. G., Smale, T. C , King, T. J., Hasenkamp, R., Thompson, R. H., J. Chem. Soc, 
Perkin Trans., 1976,1, 1165. 
6 Mischer, L. A., Chem. Rev., 2005,105, 559. 
7 Dizman, B., Elasri, M. O., Mathias, L. J., Biomacromolecules, 2004, (5, 514. 
8 Gould, R., Jr., Jacobs, W. A., J. Am. Chem. Soc, 1939, 61, 2890. 
9 Tonmunphean, S., Parasuk, V., Kokpol, S., Quant. Struct. Act. Relat., 2000,19, 475. 
10 Banasznski, L. A., Liu, C. W., Wandless, T. J., J. Am. Chem. Soc, 2005,127, 4715. 
11 Cheng, F., Shen, J., Luo, X., Zhu, W., Gu, J., Ji, R., Jiang, H., Chen, K., Bioorg. Med. 
Chem., 2002,10, 2883. 
12 Chang-Hu, L., Hong, H., Shin, J., Jung, M., Shin, I., Yoon, J., Lee, W., Biochem. Biophys. 
Res. Commun., 2000, 274, 359. 
13 Hare, R., The birth of Penicillin, Allen and Unwin, London, 1970, 
14 Christensen, B. G., Radecliffe, R. W., Annu. Rep. Med. Chem., 1976,11, 271. 
15 Fostel, J. M., Lartey, P. A., DDT, 2000, 5, 25. 
16 Kidwai, M., Venkataramanan, R., Rastogi, S., Sapra, P., Curr. Med. Chem. Anti-Infect. 
Agents, 2003, 2, 27. 
17 Hammond, S. M, Lambert, P. A. Antibiotics and Antimicrobial Action: Studies in Biology, 
90, Edward 
Arnold Publishers Ltd, London, 1978, 2. 
18 Hutter, R., Leisinger, T., Nuesch, T., Wehrli, W., Antibiotics and other secondary 
metabolites, Academic Press, London, 1978, 1. 
115 
19 Cragg, G. M, Newman, D. J. Pharm. Biol, 2001,39, 8. 
20 Nogrady, T., Medicinal Chemistry: A Biochemical Approach, Oxford University Press, New 
York, 1988, 358. 
21 Kahne, D., Leimkuhler, C, Lu, W., Walsh, C, Chem.Rev., 2005, 105, 425. 
22 Fisher, J. F., Meroueh, S. O., Mobashery, S., Chem. Rev., 2005,105, 395. 
23 Bronson, J. J., Barrett, J. F., Curr. Med. Chem., 2001, 8, 1775. 
24 Hedge, V. R., Patel, M. G., Horan, A. C , King, A. H., Gentle. F., Puar, M. S., Loebenberg, 
D.,J.Ant., 1998,57,464. 
25 Kohri, K., Nakajima, S., Suzuki, H., Kondo, H., Suda, H., J. Antibiot., 1992, 45, 868. 
Igarashi, M., Tsuchida, T., Kinoshita, N., Kamijima, M., Sawa, R., Naganawa, H., Hamada, 
M., Takeuchi, T., J. Antibiot., 1998, 51, 123. 
27 Omura, S., Nakagawa, A., Shibata, K., Sano, H., Tetrahedon Lett., 1982, 45, 4713. 
28 Gao, Y., Nat. Prod. Rep., 2002,19, 100. 
29 Hubbard, B. K., Walsh, C. T., Angew. Chem. Int. Ed, 2003, 42, 730 
i n 
Beauregard, D. A., Williams, D. H., Gwynn, M. N., Knowles, D., J. Antimicrob. Agents 
Chemother. 1995, 39, 781, 
31 Westwell, M. S., Gerhard, U., Williams, D. H., J. Antibiot. 1995, 48, 1292 
32 Nicolaou, K. C , Boddy, C. N., Brase, S., Winssinger, N., Angew. Chem., Int. Ed., 1999, 38, 
2096. 
33 Evans, D., Wood, M., Trotter, B., Richardson, T., Barrow, J., Katz, J., Angew.Chem., Int. 
Ed, 1998, 37, 2700. 
34 Kleinkauf, H., Von Dohren, H., Eur. J. Biochem., 1990,192, 1. 
35 Hammond, S. J., Williamson, M. P., Williams, D. H.,., Boeck, L. D., Marconi, G. G., J. 
Chem. Soc. Chem. Commun., 1982, 344. 
36 Malabarba, A., Ciabatti, R., Curr. Med. Chem., 2001, 8, 1759. 
Zhang, H., Tomoda, H., Tabata, N., Oohorig, M, Shinose, M., Takahashi, Y., Omura, S., J. 
Antibiot.., 1999, 52,29. 
38 Schimana, J., Gebhardt, K., Holtzel, A., Schmid, D. G., Sossmuth, J. M., Pukall, R., 
Fieldler, H., J. Antibiot., 2002, 55, 565. 
39 Kimura, K., Ikeda, Y., Kagami, S., Yoshihama, M., J. Antibiot., 1998, 57, 647. 
40 Magnet, S., Blanchard, J. S., Chem. Rev., 2005,105, All. 
116 
41 Vladimir, B., Chem. Biol. Antibiot,, Elsevier. New York, 1983, 5, 117. 
42 Bertram, G. K., Bas. Clin. Pharm., 7th Ed., USA, 1998, 753. 
43 Kapusnik, J. E., Hackbarth, C. J., Chambers, H. F., Carpenter, T., Sande, M. A., J. Infect. 
Dis., 1988,158, 7. 
44 Blaser, J., J. Antimicrob. Chemother., 1991, 27, 21. 
45 Chopra, I., Roberts, M, Microbiol. Mol. Biol. Rev., 2001, 65, 232. 
4 Hardman, J. G., Gilman, A. G., Limbird, L. E., Goodman Gilman's: Pharm.Therap. , 
McGraw-Hill Health Professions Division, New York, 1996, 9th Ed., 1029. 
47 Argewal, O. P., Chemistry of Organic Natural Products, Goel Publishing House, India, 
1983, 7th Ed, 127. 
48 Chopra, I., Roberts, M., Microbiol. Mol. Biol. Rev., 2001, 65, 232. 
49 Katz, L., Ashley, G. W., Chem. Rev., 2005,105, 499. 
50 Mukhtar, T. A., Wright, G. D., Chem. Rev., 2005,105, 529. 
51 Chatterjee, C, Paul, M, Xie, L., Van der Donk, W. A., Chem. Rev., 2005,105, 633. 
52 Bagley, M.C., Dale, J.W., Merritt, E.A., Xiong, X., Chem. Rev., 2005,105, 685. 
53 Berdy, J.,Adv.Appl.Microbiol, 1974,18, 309. 
54 Kompis, I. M., Islam, K., Then, R L., Chem. Rev., 2005,105, 593. 
55 Cragg, G. M., Newman, D. J., Snader, K. M., J. Nat. Prod., 1997, 60, 52. 
56 Karen, M. O., Barrett, J. F., DDT, 2005,10, 45. 
57 Pandey, R. C, Rinehart, K. L., J. Antibiot., 1976, 29, 1035. 
58 Kumar, P., Koppisch, A. T., Cane, D. E., Khosla, C, J. Am. Chem. Soc, 2003,125, 14307. 
59 Aharonowitz, Y., Cohen, G., Martin, J. F.,Annu. Rev. Microbiol., 1992, 46, 461. 
60 Paiva, N. L., Demain, A. L., Roberts, M. F., J. Microboil., 1993,12, 423. 
61 Schlegel, H. G., General Microbiology, Cambridge University Press, 6thedition, USA, 1986, 
191. 
62 Skoog, D. A., West, D. M., Holler, F. J., Fundamentals of Analytical Chemistry, 6th ed., 
Saunders College Publishing, USA, 1992, 519. 
63 Kortum, G., Seiler, M., Angew. Chem., 1939, 52, 687. 
64 Willard, H. H., Merritt, L. L., Dean, J. L., Settle, F. A., Instrumental Methods of Analysis, 
Belmont, Califonia, 1988. 
117 
65 Mayer, R. A., Encyclopedia of Analytical Chemistry, Applications, Theory & 
Instrumentation, Wiley, Sussex, 2000. 
66Hutchnison, C. R., Drug Discovery and Therapeutic medicine, 2005, 77. 
* Described in experimental section 
67 Bruice, P. Y., Organic Chemistry, Prentice-Hall, USA, 1998. 
68 Abraham, R. J., Fisher, J., Loftus, P., Introduction to NMR Spectroscopy, John Wiley & 
Sons, New York, 1988. 
69 Pavia, D.L., Lampman, G. M., Kriz, G. S., Introduction to Spectroscopy, 3r ed., Harcourt 
College Publishers, Orlando, 2001, 41. 
70 Brown, C. J., Proc. Roy. Soc, London Ser. A., 1968, 302, 185. 
71 Brown, C. J., Ehrenberg, M.,Acta Cryst., 1985, C41, 441. 
72 Harwood, L. M., Moody, C. J., Experimental Organic Chemistry: Principles and Practice, 
Blackwell Scientific Publications, Oxford, 1989, 119. 
73 O'Farell, P. H., J. Biol. Chem., 1975, 250, 4007. 
74 Klose, J., Humangetik, 1975, 26, 231. 
75 Dennison, C, A Guide to Protein Isolation, Kluwer Academic Publishers, London, 2003, 
139. 
76 Bradely, E. B., Frenzel, C. A., Water Res., 1970, 4, 125. 
77 * • 
Shapiro, A. L., Vinuela, E., Maizel, J. V., Biochem. Biophys. Res. Commun., 1967, 28, 815. 
78 McMurry, J., Organic Chemistry, Cole Publishing Company, California, 1988, 970. 
79 Kar, A., Gugnani, H. C , Madumere, U. A., Pharmazie, 1980, 35, 466. 
80 Hurley, L. H., Gairola, C , Antimicrob. Agents Chemother., 1979, 75, 42. 
81 Abell, C, Allen, F. H., Bugg, T. D. H., Doyle, M. J., Rathby, P. R., Acta. Cryst., 1988, C44, 
1204. 
82 Davis, B. D., J. Bacteriol., 1952, 64, 729. 
83 Dewick, P. M., Nat. Prod. Rep., 1992, 9, 153. 
84 Haslim, E., Shikimic Acid-Metabolism and Metabolites, John Wiley & Sons, New York, 
1993. 
85 Dewick, P. M., Medicinal natural products: A Biosynthetic approach, 2nd ed., John Wiley & 
Sons, USA, 2002. 
118 
86 Yoshida, M., Yasuda, N., Nishikata, M., Okamoto, K., Uchida, T., Matsuyama, K., J. Infect. 
Chemother., 2005, II, 182. 
87 Yoshido, O., Yasukata, T., Sumino, Y., Munekage, T., Narukawa, Y., Nishitani, Y., Bioorg. 
Med. Chem. Lett., 2002,12, 3027. 
88 Medina, H. J., Paladini, A. C , Izgierdo, I., Behav. Brain. Res., 1993, 58, 1. 
89 Dervan, P. B., Science., 1986, 232, 464. 
90 Hurley, L. H., Boyed, F. L., TIPS, 1988, 9, 402. 
91 Calfe, M. W., Coleman, J. P., Pesci, E. C , Proc. Acad. Sci., 2001, 98, 11633. 
92 Bredenbruch, F., Nimtz, M., Wray, V., Morr, M., Muller, R., Haussler, J., J. BacterioL, 
2005,187, 3630. 
93 Jensen, J. B., Egsgaard, Van Onckelen, H., Jochimsen, B. U., J. BacterioL, 1995,177, 5762. 
94 Walsh, H. A., O'Shea, K. C , Botting, N. P., BMC Biochem., 2003, 4, 13. 
95 http:// www.ebscohost.com. Accessed on the 29th October 2005. 
96 http://innsta.com/health/nutrition/vitamins/others.htm. Accessed on the 11th December 2005. 
97 Ansbacher, S., Science, 1941, 93, 164. 
98 Wyss, O., Proc. Soc. Exp. Biol, and Med., 1941, 48, 122. 
99 Rubbo, S. D., Gillepsie, J. M., Nature, 1940,148, 838. 
100 Blanchard, K. C, J. Biol. Chem., 1941,140, 919. 
101 Supniewski, Z., J., Biochem. , 1924,148, 522. 
102 Leonard, J., Lygo, B., Procter, G., Advanced Practical Organic Chemistry, 2nd ed., Blackie 
Academic & Professional, New York, 1995. 
103 Okudoh, V., Isolation and Identification of Antibiotics Producing Microorganisms From 
Natural Habitats in the KwaZulu-Natal Midlands, University Of Natal Pietermaritzburg, 2001. 
104 http://www.Sigma-aldrich.com/safc, Accessed on the 2nd of September 2005. 
119 
APPENDICES 
Table 7: Crystal data and structure refinement for anthranilic acid. 
Empirical formula C7 H7 N O2 
Formula weight 137.14 
Temperature 100(2) K 
Wavelength 0.71073 A 
Crystal system Orthorhombic 
Space group P b c a 
Unit cell dimensions a = 7.106(2) A D = 90° 
6=15.835(4) A D=90° 
c= 11.641(3) A D=90° 
Volume 1309.8(6) A3 
Z 8 
Density (calculated) 1.391 Mg/m3 
Absorption coefficient 0.103 mm' ' 
F(000) 576 
Crystal size 0.40 x 0.20 x 0.08 mm3 
Theta range for data collection 4.23 to 25.04° 
Index ranges -8<=h<=7, -18<=k<=18, -13<=1<=13 
Reflections collected 7566 
Independent reflections 1154 [R (int) = 0.1064] 
Completeness to theta = 25.00° 99.2 % 
Absorption correction Empirical (DIFABS) 
Max. and min. transmission 0.8363 and 0.4890 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1154 / 0 /103 
Goodness-of-fit on F^ 1.208 
vii 
Final R indices [I>2sigma(I)] Rl = 0.0669, wR2 = 0.1311 
R indices (all data) Rl = 0.0904, wR2 = 0.1400 
Largest diff. peak and hole 0.201 and -0.202 e A"3 
vin 
Table 8: Atomic coordinates (x 10^) and equivalent isotropic displacement parameters (A^x 
10^) for anthranilic acid. U(eq) is defined as one third of the trace of the orthogonalized UU 
tensor 














































Table 9: Bond lengths [A] and angles [°] for anthranilic acid. 






































)-C(4) 1 .399(4) 
)-H(3) 0.9500 


































































Symmetry transformations used to generate equivalent atoms: 
XI 
Table 10: Anisotropic displacement parameters (A^x 10^) for anthranilic acid. The anisotropic 
displacement factor exponent takes the form: -2U^[hra*^U^ + ... + 2 h k a* b* U^ J 









































-2(1) 1(1) 4(1) 
0(1) 0(1) 5(1) 
1(1) 9(2) 2(1) 
-3(1) 5(1) -2(1) 
-6(1) -2(1) 3(1) 
-3(1) 0(1) 5(1) 
-3(1) -1(1) 6(1) 
-2(1) -3(1) -1(1) 
1(1) 1(1) -2(1) 
0(1) -2(1) -4(1) 
xn 
Table 11: Hydrogen coordinates (x 10^) and isotropic displacement parameters (A^x 10^) 
for anthranilic acid. 
Atom x y z U(eq) 
H(2) 4027 6288 -1870 30 
H(3) 6791 7056 -2034 36 
H(4) 8738 7226 -419 33 
H(5) 7886 6661 1335 32 
H(1N) 5840(50) 5880(20) 2480(30) 52(10) 
H(10) 260(50) 5210(20) -860(30) 63(12) 
H(2N) 3860(50) 5410(20) 1890(30) 43(9) 
xiii 














































Symmetry transformations used to generate equivalent atoms: 
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